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1 INTRODUCTION 
Peptide-receptor radionuclide therapy (PRRT) has shown promising results in the 
treatment of tumours with high expression of somatostatin receptors such as 
neuroendocrine tumours (NETs) and meningioma, displaying high sensitivity and 
specificity [1-5]. However, PRRT can produce high renal and red marrow (RM) 
toxicity, the kidneys usually being the dose-limiting organ in this therapeutic modality 
[3]. Despite the positive results achieved with PRRT and its high therapeutic potential 
[3, 6], the routinely applied treatment can be improved by choosing an individually 
optimised peptide amount and administered activity for each patient, as shown by 
Kletting et al. [4]. By doing this, an increased therapeutic index (directly associated 
with the treatment outcome) can be achieved [4]. Previously, a method was 
presented, which can be applied to determine the optimal peptide amount and activity 
leading to a maximum tumour-to-kidney biologically effective dose (BED) ratio [4]. 
This method was applied to optimise the outcome of PRRT with 90Y-DOTATATE in 
nine patients, assuming a maximum kidney BED of 20 Gy2.5 per cycle (for a total of 2 
cycles) in the optimisation process and excluding all the combinations of amount and 
activity leading to RM BEDs higher than 1 Gy15 [4].  Although the method developed 
by Kletting et al. [4] represents an important step forward towards individualised 
treatment planning in PRRT, some additional features are required to achieve clinical 
applicability: 
1. Multiple tumour lesions need to be considered simultaneously.  
Individually applying the optimisation process to each considered 
lesion/metastasis would lead to as many different “optimal” treatment plans as 
considered lesions. A suitable treatment planning algorithm must consider 
multiple tumour lesions simultaneously delivering a single plan to apply to the 
patient. This is of great relevance for patients with multiple lesions/metastases. 
2. Multiple potentially dose-limiting organs (e.g. the kidneys and the RM) need to 
be considered simultaneously. 
Although combinations of amount and activity leading to RM BEDs higher than 1 
Gy15 are correctly excluded in the method presented by Kletting et al. [4], this is 
done after considering only the kidney BED constraint to determine the optimal 
activity for each peptide amount. As no recalculations (e.g. considering the RM 
BED constraint) of the optimal activities for the respective excluded amounts are 
performed, suboptimal treatment plans may be derived. 
3. Constraints in the radiopharmaceutical synthesis need to be accounted for. 
This characteristic is important in a treatment planning algorithm for PRRT to 
guarantee that the delivered combinations of amount and activity can be 
synthesised. 
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Therefore, the aim of this work was to develop a clinically applicable algorithm for 
treatment planning in PRRT based on the method presented by Kletting et al. [4]. 
Furthermore, to demonstrate the applicability and advantages of the developed 
algorithm, an in silico (i.e. based on computational simulations) clinical trial applying 
the algorithm to 177Lu-DOTATATE PRRT in nine virtual patients was conducted. 
The thesis is structured as follows: 
 Background.  
Different fundamental concepts used in the presentation of the developed 
treatment planning algorithm are introduced in this chapter. Firstly, a general 
overview of molecular radiotherapy (MRT) is given: this includes short 
descriptions of the characteristics of the used radiopharmaceuticals and of the 
main applied techniques. In the second and third parts of the Background chapter 
the concepts of pharmacokinetics and physiologically-based pharmacokinetic 
(PBPK) models are introduced. A good understanding of these concepts is 
required as the developed treatment plan algorithm is based on PBPK models. In 
the fourth part of this chapter, the concepts of dosimetry and BED are explained 
in detail. These concepts are also fundamental to correctly understand the 
developed algorithm as BED constraints are to be considered to achieve 
treatment plans that can be safely applied to the patients. Lastly, the current state 
of treatment planning in MRT is presented to put the developed treatment 
planning algorithm in context. 
 Presentation of the developed treatment planning algorithm. 
In this section the developed concepts of overall BED (oBED) and overall tumour 
control probability (oTCP) are described. In addition, the concept of virtual patient 
is described and the characteristics of the virtual patients (i.e. characteristics of 
the patients and of the PBPK model) used in the conducted in silico clinical trial 
are presented. Lastly, in this section, the general workflow of the developed 
treatment planning algorithm is given, which is the most important part of the 
whole manuscript. 
 In silico clinical trial. 
In this section, optimal plans are obtained by applying the developed treatment 
planning algorithm to simulations of pharmacokinetics with 177Lu-DOTATATE 
using nine virtual patients. Subsequently, the derived optimal plans and a typically 
delivered plan for 177Lu-DOTATATE are compared considering tumour BED 
values and values for the developed concept of oTCP.  
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2 BACKGROUND 
2.1  Molecular Radiotherapy 
Molecular radiotherapy (MRT) is a predominantly systemic therapy for the treatment 
of cancer in which a radiopharmaceutical or radionuclide is administered to patients 
to kill or sterilise tumour cells [7]. This kind of therapy, which has been already used 
for more than 50 years, exploits biological and physiological differences between the 
tumours or tumour-host tissues and the normal tissues to increase the accumulation 
of the radiopharmaceutical [8-10]. Therefore, the radiation absorbed dose, in a region 
of interest (i.e. the tumour or tumour-host tissue) [8-10]. MRT has been used for the 
treatment of multiple types of cancer, for both primary tumours and metastases [11, 
12]. The most commonly used mechanism in MRT is to administer 
radiopharmaceuticals which target peptide-receptors (peptide-receptor radionuclide 
therapy (PRRT)) or antigens (radioimmunotherapy) overexpressed in tumour cells [8, 
9, 11, 13, 14]. Specific characteristics of the tumour-host tissue have also been 
exploited to generate higher accumulation of the radiopharmaceutical or radionuclide 
in the region of interest [10, 11, 15]. Radioactive iodine, for example, has been used 
for thyroid cancer treatment as thyroid cells have a high uptake of iodine to produce 
hormones [10, 11, 15]. However, as MRT is a systemic therapy and the targeted 
antigens, receptors or cellular mechanisms may be presented not exclusively on the 
tumours or tumour-host tissues, MRT may also produce considerable damage to 
normal tissues. Furthermore, the biodistribution of the radiopharmaceuticals over 
time (i.e. pharmacokinetics) is patient-specific because of inter-individual anatomical 
and physiological differences [4, 7, 16-19]. Therefore, the main challenges in MRT 
are: 
a) Synthesis of radiopharmaceuticals with high accumulation in the target 
tissue/cells (i.e. tumour or tumour-host tissue/cells) and low accumulation 
in normal tissues/cells. 
 
b) Individualised treatment planning aiming at maximising the number of 
killed/sterilised tumour cells while avoiding high toxicity to normal tissues 
for a given radiopharmaceutical. 
 
2.1.1 Radiopharmaceuticals in Molecular Radiotherapy 
Radiopharmaceuticals consist of two main components: a carrier and a radionuclide 
[20]. The carrier is usually a substance with high affinity to tumour-associated target 
molecules which allows high accumulation in the tumour region or tumour-host tissue 
[11, 20]. The most frequently used carrier molecules are: small molecules, peptides, 
proteins and antibodies [20, 21]. The radionuclide is attached to the carrier and emits 
radioactive particles which can kill/sterilise tumour cells by producing direct or indirect 
DNA damage [22]. Emitters of α particles, β particles or Auger electrons are used for 
4 
 
therapy [20]. Nuclides emitting γ radiation or positrons can also be attached to 
carriers but these are mostly used for imaging purposes [20]. Some nuclides allow 
both therapy and imaging as they produce more than one type of emission (e.g. 177Lu 
emits β- particles (used for therapy) and γ radiation (used for imaging) [3, 14, 20]). 
The radioactivity (i.e. activity) of a nuclide is determined by its radioactive half-life T1/2 
which is the time in which the number of radiation decays (i.e. disintegrations) per 
second is reduced to half its initial value. Nuclides with long radioactive half-lives 
(e.g. 90Y (64.8 h) and 177Lu (153.6 h)) are commonly used for therapy while nuclides 
with short radioactive half-lives (e.g. 68Ga (67.6 min) and 18F (110 min)) are more 
common for imaging [23]. 
Multiple combinations of carrier molecules and nuclides are used in molecular 
radiotherapy [12]. To label carrier molecules with radionuclides two main methods 
are used: direct and indirect labelling [21]. Direct labelling consists in modifying the 
carrier molecule to create binding sites for the radionuclide [21]. Indirect labelling 
consists in using additional structures which bind to both the carrier and the 
radionuclide, acting as a bridge between them [21]. The used labelling method 
depends on the properties of both the radionuclide and the carrier [24]. Examples of 
direct and indirect labelling are presented in Figure 1 [24]. 
 
 
Figure 1. Labelling techniques [24]. A: Direct labelling. The 
131
I radionuclide (dark blue) is directly 
attached to a modified section (side chain) of the carrier. B: Indirect labelling using an additional 
structure. The 
18
F is first attached to an additional structure (red) which also binds the carrier. C: 
Indirect labelling using chelators. A chelator (light red region) is a special molecular construction 
mostly used for labelling with metallic radionuclides (e.g. 
90
Y (orange)) [24]. 
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In practice, not all the carrier molecules can be labelled during the synthesis of 
therapeutic radiopharmaceuticals (usually < 5 % of carriers are labelled). This 
generates, in principle, two kinds of substances: labelled and unlabelled carriers, 
which compete for the available target molecules (this competition is described by 
nonlinear equations). Moreover, radionuclides are produced with an activity which is 
limited depending on the nuclide itself and on the production technique [25]. These 
factors limit the maximum achievable molar activity (i.e. activity per mole of 
radiopharmaceutical) which is proportional to the maximum achievable specific 
activity (i.e. activity per gram of radiopharmaceutical) [26]. Molar activity is usually 
measured in units of [MBq/nmol] and specific activity in units of [MBq/μg] [25, 26]. 
 
2.1.2 Peptide-Receptor Radionuclide Therapy 
As some tumours overexpress peptide-receptors, peptides with high affinity to the 
overexpressed receptors which are labelled with therapeutic radionuclides (i.e. α, β 
and or Auger electron emitters) are used for the treatment of these kinds of tumours 
[20]. Molecular radiotherapy using labelled peptides to target the corresponding 
peptide-receptors in the tumour cells is called peptide-receptor radionuclide therapy 
[3, 13]. This radiotherapy technique is relatively new, as it was first introduced in the 
1990s [3]. In PRRT, β- emitters (e.g. 90Y and 177Lu) are commonly used for labelling 
peptides [3, 13, 14]. However, other kinds of radionuclides (e.g. 111In, an Auger 
electron emitter) are also utilised in practice [3, 12, 27]. The most explored targeted 
peptide-receptors in PRRT are the group of somatostatin receptors (SSTR), with the 
SSRT type 2 (SSRT2) being of great interest due to its high expression in 
neuroendocrine tumours (NETs) and other tumours of the nervous system (e.g. 
meningioma and neuroblastoma) [3, 5]. Other receptors that have been targeted in 
PRRT are for example the gastrin-releasing peptide receptors (GRPRs), which 
overexpress in gastrointestinal tumours [28, 29]. 
According to the effect produced by the drug-receptor interaction, carrier peptides 
can be classified as [30, 31]: 
 Full agonists: produce the same biological response as the native peptide. 
 Partial agonists: produce a fraction of the biological response produced by 
the native peptide. 
 Superagonists: produce a higher biological response than the native peptide 
[31]. 
 Antagonists: do not produce any biological effect and only make the bound 
peptide-receptors unavailable for other molecules.  
 Inverse agonists: produce a partial or full biological response opposite to the 
native peptide response. 
Antagonist carrier peptides may be desirable as they do not produce complex 
biodynamic interactions (i.e. modifications of metabolic functions) which could 
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generate adverse side effects [30, 32, 33]. In addition, although peptide antagonists 
do not undergo specific internalisation, which could reduce their accumulation in the 
target tissue, the superiority of SSTR2-antagonist radiopharmaceuticals has been 
demonstrated [33]. 
Two of the most commonly used carrier peptides in PRRT are [DOTA0,Tyr3]-
octreotide (DOTATOC) and [DOTA0,Tyr3,Thr8]-octreotide or [DOTA0,Tyr3]-
octreotate (DOTATATE) [3, 13, 14]. These peptides are both SSRT2 agonists [3, 33]. 
For these two radiopharmaceuticals, DOTA indicates the used bifunctional chelating 
molecule (i.e. binds both the carrier and the radionuclide) and the rest of the name 
description corresponds to the modified carrier molecule [3]. DOTATOC and 
DOTATATE are usually labelled with 90Y or 177Lu for therapy and with 68Ga and 111In 
for imaging [3, 13, 14]. 
Although PRRT has shown promising results, especially in the treatment of tumours 
with high expression of SSTRs (e.g. NETs and meningioma), this therapeutic 
technique may produce high renal and red marrow (RM) toxicity, the kidneys usually 
being the dose-limiting organ [1-5, 34]. Therefore, to reduce the nonspecific uptake of 
radiopharmaceutical in the kidneys, a solution of amino acids (e.g. lysine and 
arginine) is routinely co-administered before the infusion of the radiopharmaceutical 
[35]. 
 
2.1.3 Radioimmunotherapy 
Molecular radiotherapy performed with labelled antibodies targeting antigens 
overexpressed in the tumour cells is called radioimmunotherapy (RIT) [18]. This 
therapeutic modality, used for more than 50 years, can be administered intravenously 
but also intracavitary, e.g. in the peritoneum [8, 9]. RIT has been used mostly for the 
treatment of haematological malignancies (e.g. leukaemia or lymphoma) but can also 
be used to treat solid tumours [8, 9]. In addition, RIT has been applied for 
immunosuppression (i.e. weakening of the immune system to avoid immune 
reactions, e.g. as preparation for stem cell transplant) [18]. Some of the targeted 
antigens in RIT are the haematopoietic cluster of differentiation (CD) antigens (e.g. 
CD33, CD45 and CD66) for different types of leukaemia, and the prostate-specific 
membrane antigen (PSMA) for prostate cancer [8, 17, 19]. In RIT, the usual organs at 
risk (OARs) are the red marrow, the kidneys, the salivary glands and the liver [18, 19, 
36]. However, the dose-limiting organ in RIT depends on the selected antibody and 
nuclide and on patient-specific pharmacokinetics [16, 37]. 
According to their origin, antibodies can be classified as monoclonal and polyclonal 
antibodies [38]. Monoclonal antibodies (mAbs) are produced from a single B 
lymphocyte clone and are therefore all identical [38]. As a consequence, mAbs target 
the same antigen and the same epitope (i.e. binding site in the antigen) [38]. 
Polyclonal antibodies (pAbs), in contrast, are produced from different B lymphocytes 
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which recognise the same antigen and hence, they are not homogenous [38]. Thus, 
pAbs bind the same antigen but at different epitopes [38]. Because of the higher 
specificity of mAbs (they target the same epitope in the same antigen), mAbs have 
been the standard selection for the treatment of cancer for more than 20 years [39]. 
A special modality of RIT is pretargeted radioimmunotherapy (PRIT). PRIT, 
introduced in the 1980s, is a two- or multistep technique, which fundamentally 
consists in administering the antibody molecules and the nuclide molecules 
independently [12]. First, the antibody molecules with additional binding structures 
are administered [12]. After some time, in which it is expected that the antibodies 
(with the additional structures) are mostly cleared from the blood and attached to the 
antigens, the radioactive molecules are administered [8]. The administered 
radioactive molecules have extra structures with high affinity to the structures added 
to the antibodies. Consequently, the radioactive molecules will bind the antibodies 
bound to the antigens (Figure 2, A) [40].  
 
 
Figure 2. Pretargeted radioimmunotherapy. A) Pretargeted radioimmunotherapy in which one 
radioactive molecule with additional structure B binds one previously administered antibody with 
additional structure A bound to the antigen in the tumour cell. The additional structures A and B 
are complementary or have a very high affinity between them [40]. B) Pretargeted 
radioimmunotherapy enhancing the number of radioactive molecules per bound antibodies. In this 
configuration, the additional structure in the antibody can bind multiple radioactive molecules [12]. 
C) Pretargeted radioimmunotherapy with increased specificity due to the stronger binding (double 
binding) to the antibodies [12]. 
 
PRIT is used to improve the therapeutic index (i.e. the ratio between the tumour 
absorbed dose and the absorbed dose in the dose-limiting organ, e.g. the red 
marrow) and to reduce the overall absorbed dose in the body. An overall absorbed 
dose reduction is achieved as the small radioactive molecules rapidly penetrate the 
tumour site where are highly bound to the modified antibodies [8, 9, 12]. In addition, 
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the unbound radioactive molecules are easily excreted in the urine which lowers the 
overall absorbed dose to the OARs and to the body [8]. Furthermore, using this 
technique allows to attach multiple radioactive molecules to a bound antibody 
(producing a higher therapeutic effect) or to increase the specificity by binding a 
radioactive molecule to more than one bound antibody (Figure 2, B and C) [12]. 
  
2.2  Pharmacokinetics 
Pharmacokinetics (also called drug biokinetics or simply biokinetics) is the study of 
the absorption, distribution, metabolism and excretion (ADME) over time of a 
pharmaceutical (or radiopharmaceutical) administered to an organism [37, 41]. 
Pharmacokinetics depends on multiple factors such as drug-specific, organism-
specific and administration-specific characteristics, which determine the ADME for 
different scenarios and individuals. 
Absorption is the process in which the administered pharmaceutical passes from the 
administration site to the blood [37, 41]. The process of absorption applies mostly for 
orally administered drugs (or indirectly administered drugs) which can be eliminated 
through the gastrointestinal tract (or through other ways) before reaching the main 
bloodstream [37]. Therefore, for orally administered drugs, the concept of drug 
bioavailability (i.e. fraction of the administered drug, which reaches the main 
bloodstream) is of relevance [37, 41]. For intravenously administered drugs, the 
concept of absorption, and therefore bioavailability, is not of high relevance as the 
pharmaceutical is administered directly to the bloodstream (in principle, 100 % 
bioavailability). However, binding of the pharmaceutical to some serum proteins (e.g. 
albumin) or to erythrocytes can reduce the effective available fraction of the 
administered drug (i.e. effective bioavailability) [37, 42]. 
Distribution is the process in which the bioavailable pharmaceutical passes from the 
main bloodstream to the organs and tissues [37, 41]. Distribution directly depends on 
the blood/plasma volume in the central circulatory system, the organ/tissue blood 
flow (or plasma flow) and the vascular volume (i.e. the amount of blood/plasma in an 
organ or tissue). These parameters determine the drug transfer rate (in units or 
subunits of [min-1]) from the main bloodstream to the organs/tissues and from the 
organs/tissues back to the main bloodstream [4]. An additional process involved in 
the distribution of a pharmaceutical is permeability. In simple words, permeability can 
be defined as the amount of drug passing from the organ vascular volume, also 
called vascular space, to the organ interstitium (i.e. space around the organ cells). 
This process is highly important for most pharmaceuticals because if a drug does not 
reach the organ interstitium it cannot interact with the organ cells. 
Metabolism, for a pharmaceutical, is the decomposition of a molecule in 
submolecules allowing/facilitating further interactions or excretion [37]. The main 
metabolic organ is the liver, however, other organs/tissues such as the intestines, the 
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kidneys, the lungs, the brain and the blood can perform metabolic functions [37]. The 
submolecules resulting after a metabolic process are called metabolites. 
Excretion is an elimination process in which waste substances are taken outside of 
an organism (e.g. to the intestines or the bladder). Once a pharmaceutical enters the 
main bloodstream, it will be mostly excreted by the kidneys through the urine or by 
the liver through the bile, which is subsequently eliminated through the stools [37, 
41]. 
For radiopharmaceuticals labelled with a nuclide which allows imaging (e.g. 18F, 
68Ga, 111In or 177Lu), the pharmacokinetics in different organs/tissues can be 
determined/estimated using series of radiation-based images (e.g. positron-emission 
tomography (PET), single-photon emission computed tomography (SPECT) or 
gamma camera images). Radiopharmaceuticals sharing the same carrier (e.g. 68Ga-
DOTATATE, 177Lu-DOTATATE and unlabelled DOTATATE) are usually assumed to 
have the same pharmacokinetic characteristics. The activity measured in the 
organ/tissue varies over time because of the drug pharmacokinetics and the nuclide 
radioactive decay. The activity measured in a tissue at a time-point is closely related 
to the amount of radiopharmaceutical in the tissue at that specific time. The graphical 
representation of the variation of the activity over time in a region of interest (e.g. 
organ, tissue, blood or whole body) is called time-activity curve (TAC) (Figure 3). 
TACs are sometimes presented in relative units of activity (e.g. [MBq/g], [MBq/ml], % 
injected activity, % injected activity/ml) as the data retrieved from radiation-based 
images (e.g. PET, SPECT and gamma camera images) and blood activity 
measurements are usually given in relative units. The area lying below a TAC is 
called area under the curve (AUC) and represents the total amount of radiation 
produced by the radiopharmaceutical accumulated over time (i.e. time-integrated 
activity, in units of [Bq·s] [43]) in a tissue. However, this is only valid when the TAC is 
represented in absolute units of activity (e.g. [MBq]) (Figure 3). The AUC can thus be 
used to calculate the absorbed dose in the tissue [44]. However, the absorbed dose 
in a tissue does not only depend on the amount of radiation produced in the specific 
tissue but also on radiation generated in surrounding tissues [44, 45]. Thus, more 
complex dosimetric calculations are to be performed to determine the total absorbed 
dose in the organs/tissues [44]. 
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Figure 3. Time-activity curve and area under the curve. The activity measurements retrieved from 
a series of radiation-based images (purple dots) are used to generate a fitted time-activity curve 
(TAC) (black solid line). The area under the curve (AUC) (light blue) is the region lying below the 
fitted TAC. Example data from a female patient of 67 kg after a bolus administration of 178.5 MBq 
(32 nmol) of 
68
Ga-NeoBOMB1. 
 
As the amount of measured data points is limited, TACs are usually generated by 
fitting a sum of exponential functions to the measured data (Eq. (1)). Exponential 
functions are used as both the radioactive decay and most biological processes 
follow exponential kinetics [46]. TACs expressed as fitted functions allow prediction of 
the activity for time-points not considered during the imaging protocol, such as 
intermediate time-points and time-points after the last measured data point. Fitted 
TACs also allow to perform better calculations/estimations of the AUC by integrating 
the TACs from time zero to infinity. As the radioactive decay rate (    ) is a known 
parameter (              ⁄ , where T1/2 is the half-life of the radioactive nuclide), 
the fitting function used for the TACs is usually presented as [46]: 
      ∑    
                   (1) 
where A(t) is the activity over time, Ai values are linear coefficients and    values are 
exponential coefficients. The fitting process consists in obtaining the Ai and   values 
better supported by the measured data [46]. However, the number of exponential 
functions used to fit a TAC to the data is not fixed (e.g. TACs can be fitted using one, 
two, three or more exponential functions). Therefore, to avoid over- or underfitting of 
the data, the Akaike information criterion (AIC) is used [46]. AIC is a statistical 
analysis used to determine the likelihood of a model (e.g. a function) among a group 
of models being best supported by the measured data [46]. AIC considers the 
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differences between the fitted function and measured data (in this case, the sum of 
squared errors (SS)) as well as the number of parameters (e.g. Ai and    values) and 
the number of data points [46]. Thus, AIC is used to determine the optimal number of 
exponential functions to use for fitting each TAC [46]. AIC is also used with more 
complex systems such as physiologically-based pharmacokinetic (PBPK) models to 
determine the PBPK model best supported by the measured pharmacokinetic data. 
 
2.3  PBPK Models 
A physiologically-based pharmacokinetic (PBPK) model is a compartment-based 
mechanistic model used to describe drug pharmacokinetics [47]. What differentiates 
PBPK models from other mechanistic pharmacokinetic models is the use of 
anatomical, physiological and drug-specific parameters, which makes PBPK models 
the most comprehensive type of pharmacokinetic models [47]. The constitutive 
compartments of a PBPK model represent anatomical or functional regions of interest 
(ROIs) which can be defined by considering a group of organs/tissues, a single whole 
organ/tissue or a subpart of an organ/tissue. The value of a compartment at a 
specific time-point corresponds, directly or indirectly, to the amount of the modelled 
substance at that particular time in the region represented by the compartment. The 
connections between compartments are defined by physiological connections 
between organs or tissue regions (e.g. blood flows) and represent the transfer rates 
of the drug from one compartment to another. The values of the transfer rates in a 
PBPK model, in units or subunits of [min-1], are calculated based on anatomical, 
physiological and drug-specific parameters. Depending on the complexity of the 
PBPK model, some of or all the following parameters can be considered to determine 
the model transfer rates: vascular volumes, plasma flows, permeability values, 
interstitium volumes, intracellular volumes, association rates (i.e. binding rates), 
dissociation rates (i.e. unbinding rates), metabolic rates, receptor/antigen densities, 
receptor/antigen synthesis rates, receptor/antigen degradation rates, receptor/antigen 
recycling rates, nonspecific uptake rates, internalisation rates and excretion rates [4]. 
For PBPK modelling of radiopharmaceuticals, labelled and unlabelled (or radioactive 
and nonradioactive) substances are independently considered in the model and are 
connected by the radiation decay rate     . Labelled and unlabelled substances are 
usually assumed to have the same pharmacokinetics [4], even though they have 
different molecular structures and therefore different pharmacokinetic characteristics 
(e.g. affinity and permeability). Labelled and unlabelled substances compete in a 
nonlinear manner for the available target molecules. 
The simplest PBPK model (considering not only the central circulatory system) is a 
two-compartment model, which is usually represented by a schematic such as in 
Figure 4. 
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Figure 4. Two-compartment PBPK model. Compartments are represented by circles and transfer 
rates by arrows indicating the transfer direction of the substance. The right-hand side 
compartment represents a region of interest (ROI) and the left-hand side compartment represents 
the rest of the body. The parameter I(t) represents the drug administration function (i.e. input 
function). The parameter k1 is the transfer rate from the rest of the body to the ROI, k2 is the 
transfer rate from the ROI to the rest of the body and k3 is the excretion rate. 
 
Two differential equations mathematically describe the two-compartment PBPK 
model presented in Figure 4 and are formulated as follows [48]: 
         
  
 
     
  
                                      (2) 
        
  
                             (3) 
where          is the amount of substance in the rest of the body,         is the 
amount of substance in the ROI,      is the input function and k1, k2 and k3 are the 
transfer rates as described in Figure 4. For administering a total amount of substance 
A0 using an intravenous bolus administration schedule (i.e. instant administration; in 
practice, administration in < 3 min), it can be assumed that            and that the 
initial conditions to solve the system of differential equations are:          and 
       [48]. For administration schedules using a constant administration rate R0, it 
can be assumed that             during the administration time and zero 
otherwise, and that the initial conditions are:         and       . Varying 
administration schedules can also be applied. For drugs indirectly administered (e.g. 
orally) the bioavailability over time needs to be considered to determine the input 
function     . 
More complex PBPK models considering multiple organs and subparts of the organs 
have been developed to achieve a higher descriptiveness of the pharmacokinetics 
[4]. These PBPK models require the solution of more complex systems of differential 
equations (sometimes nonlinear systems). A whole-body PBPK model considering 
multiple organs and subparts of the organs is shown in Figure 5 [4]. 
13 
 
  
Figure 5. Whole-body PBPK model [4]. A) Main structure of the PBPK model. The organs are 
connected via the blood flow according to the human physiology. The model considers the arterial 
and venous circulatory systems independently and considers, in addition, the binding of the 
substance to serum proteins. B) Modelling of the organ subparts. Individual compartments for the 
vascular space, interstitial space, cellular membrane and intracellular space are considered for 
most organs. Transfer rates are based on physiological and drug-specific parameters. Labelled 
(left) and unlabelled (right) substances are independently considered and are linked by the 
radiation decay rate     . 
 
Ideally, all the parameters of a PBPK model are known for each individual. However, 
in practice, many parameters are unknown or, in a better case scenario, known for a 
group of individuals of the same species or of another species. In addition, some 
parameters may present a large inter-individual biological variability [16]. Therefore, 
some model parameters are estimated using allometric scaling or need to be fitted 
(best individually) to measured data [16]. Allometric scaling consists in estimating 
anatomical and physiological parameters based on data from the same or different 
species [49]. Three main types of parameters are used to fit a PBPK model to 
measured data: fixed, adjustable and Bayes parameters [50]. Fixed parameters are 
used when there is a high certainty about the parameter value. Adjustable 
parameters are used when nothing or very little is known about the parameter. Bayes 
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parameters (i.e. based on a known distribution) are used when data from a group of 
individuals is available [51]. However, for some authors, defining which parameters 
need to be considered as fixed, adjustable or Bayes when fitting a PBPK model to 
measured data can be considered an art form. Nowadays, there are specialised 
pieces of software which facilitate the processes of building PBPK models and fitting 
them to measured data (e.g. SAAM II [50]).  
Once a PBPK model is validated with measured data, simulations of 
pharmacokinetics varying several parameters such as the administered amount of 
pharmaceutical or the administration schedule can be performed. The possibility of 
performing simulations of diverse scenarios allows the use of PBPK models for 
multiple purposes such as improving imaging protocols, planning therapy, optimising 
clinical trials and performing in silico clinical trials [52]. In addition, for 
radiopharmaceuticals with the same carrier and assuming the same 
pharmacokinetics, a PBPK model generated with data for one radiopharmaceutical 
(e.g. 111In-DOTATATE) can be easily adapted to another radiopharmaceutical (e.g. 
177Lu-DOTATATE) by changing the radioactive decay rate     . This increases the 
applicability of PBPK models. 
 
2.4  Dosimetry in Molecular Radiotherapy 
As indicated by its name, dosimetry consists in measuring dose. Dosimetry in 
molecular radiotherapy is also called internal dosimetry as the radiation is produced 
inside the body. In MRT two kinds of doses are of relevance: radiation absorbed dose 
(i.e. amount of deposited energy in a tissue) and biologically effective dose (BED) 
(i.e. representation of dose accounting for the biological effect in a tissue) [53]. The 
calculation of the BED considers the radiation absorbed dose in the tissue, the 
sensitivity of the tissue to the specific kind of radiation and the tissue repair during the 
radiation exposure. Thus, the correctness of the BED calculations depends on the 
measurement accuracy of the radiation absorbed doses. In MRT, dosimetry of the 
radiation absorbed dose (also called absorbed dose or physical dose) consists of two 
main steps:  
1. Measurement of the time-integrated activity values produced by the 
radiopharmaceutical accumulated in the ROIs (e.g. in the main organs and 
tissues) [45]. 
2. Calculation of the absorbed doses based on the time-integrated activity 
measurements in the ROIs. 
The measurement of the activity, and therefore the calculation of the time-integrated 
activity, in the ROIs is founded on quantitative radiation-based images (e.g. PET, 
SPECT or gamma camera images). From these images, the total amount of 
radioactive emissions generated by the radiopharmaceutical over a period of time in 
each ROI (e.g. an organ/tissue) can be determined. However, to achieve accurate 
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quantification, multiple correction factors are to be applied to the images [45, 54]. The 
most relevant corrections applied to quantitative radiation-based images are: 
attenuation correction, dead-time correction, sensitivity correction, background 
correction and scatter correction [45, 54]. Attenuation correction accounts for the 
produced radiation emissions which are absorbed in the imaged object (e.g. the 
body) and therefore do not reach the radiation detectors. Dead-time correction needs 
to be performed when the time interval between radiation emissions reaching a 
radiation detector is shorter than the processing time capacity of the system. Dead-
time correction is therefore of high relevance for high-activity measurements [45, 54]. 
The correction for the sensitivity of a radiation detector system consists in ensuring 
accurate transfer functions associating the received events with the delivered activity 
values. The sensitivity of a detector system depends on the energy and type of the 
measured radiation. Therefore, the type of nuclide used needs to be considered 
when defining the system transfer functions to use during image reconstruction [45, 
54]. Background correction considers the radiation emissions produced in regions 
adjacent to the ROI, which may alter the resulting measurements. Scatter correction 
accounts for the trajectory deviations of the radiation emissions produced by the 
interaction with the matter of the imaged object. The corrected activity data are 
subsequently used to generate TACs and to calculate the time-integrated activity in 
the ROIs [45]. 
Time-integrated activity values are then used to calculate the absorbed doses in the 
ROIs. The calculation of the absorbed dose in a ROI considers radiation produced 
both in the respective ROI and in other ROIs. Thus, ROIs can be classified as source 
regions (i.e. where radiation is produced) and target regions (i.e. where radiation is 
absorbed). The radiation characteristics, the mass of the target region and the spatial 
distribution of the source region (rS) and the target region (rT) define factors to 
determine the absorbed dose in the target region per unit of activity in the source 
region          (also called dose factors or S values) [43, 55].  
Time-integrated activity values can also be normalised by dividing them by the 
administered activity    (in units of [Bq]). Normalised time-integrated activity values 
are called time-integrated activity coefficients (TIACs). Thus, based on the time-
integrated activity value in a source region  ̃      (in units of [Bq·s]), the TIAC in a 
source region  ̃      (in units of [s]) is defined as: 
 ̃      
 ̃     
  
          (4)   
where   is the radiation exposure time. TIACs were formerly called residence times 
because of their temporal units. Using the factors          (in units of [Gy/Bq]) 
between the target region and the considered source regions, the injected activity    
and the TIACs  ̃      for all the considered source regions, the absorbed dose rate 
(i.e. dose rate) and the absorbed dose in a target region are defined as: 
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  ̇         ∑                
 
          (5) 
          ∑  ̃              
 
         (6) 
where  ̇      is the dose rate over time in the target region (in units of [Gy/s]) 
and       is the absorbed dose in the target region after the exposure time   (in 
units of [Gy] = [J/kg]). The subscripts rS and rT respectively stand for source region 
and target region, while N is the number of considered source regions. The 
parameter        is the fraction of the administered activity over time for each source 
region. The factors          are specific for each nuclide and for each combination of 
source region and target region. Therefore, tables with values for         , in which 
the source and target regions are different body organs/tissues, are available in the 
literature and are incorporated in software used for internal dosimetry (e.g. 
OLINDA/EXM) [44, 56]. The TIACs ( ̃      values) of the considered ROIs are the 
common input values for internal dosimetry software. A TIAC for the rest of the body 
(i.e. the total body excluding the selected ROIs) should also be calculated and 
entered as an input value [44]. Some additional features such as the frequency of 
bladder voiding can be considered too when performing dose calculations in some 
pieces of software for internal dosimetry. 
 
2.4.1 Biologically Effective Dose 
Ionising radiation absorbed in tissue can produce direct or indirect DNA damage [57]. 
Direct damage is produced when ionising radiation interacts with DNA molecules 
resulting in bond breaks [57]. Indirect DNA damage is produced when ionising 
radiation interacts with molecules adjacent to the DNA structure generating free 
radicals which subsequently interact with the DNA producing bond breaks [57]. 
Single- (SSB) or double- (DSB) strand breaks can occur in the DNA structure after 
interaction with ionising radiation. However, there are several cell mechanisms that 
allow complete or partial DNA repair of both SSB and DSB [58]. Depending on the 
produced DNA damage, an irradiated cell can completely recover, be sterilised (i.e. 
cannot further proliferate but it is still functional), mutate or undergo apoptosis (i.e. 
cell death) [58]. Strand breaks can produce cell death when the repair mechanisms 
cannot repair the DNA damage (DSB are more likely to produce cell death than SSB) 
[57, 59]. Several models have been used to describe the effect of radiation on cells, 
among which the linear-quadratic (LQ) model is the most commonly accepted and 
used one [60]. The LQ is a mechanistic model that describes the fraction of cells that 
survive after exposure to ionising radiation (i.e. survival fraction (SF)) [60]. Thus, SF 
values represent the probability of survival for a cell after radiation exposure. Four 
main parameters are considered in the LQ model for the calculation of the SF: 
absorbed dose, lethal damage (i.e. cell kill produced by a single radiation emission, 
also called single-hit cell kill), sub-lethal damage (i.e. cell kill produced by different 
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radiation emissions) and the relationship between damage repair rate and dose rate 
[53, 61].  Thus, according to the LQ model, SF is described as: 
               
 
               (7) 
where   (in units of [Gy-1]) is the parameter accounting for lethal damage,   (in units 
of [Gy-2]) is the parameter taking into account the sub-lethal damage,   is the Lea-
Catcheside factor representing the relationship between dose rate and repair rate 
and   is the absorbed dose [60]. The   factor is defined as: 
      
 
  
 ∫  ̇    (∫  ̇                   
 
 
)    
 
 
   (8) 
where   is the radiation exposure time,   and   are integration time variables and  , 
 ̇    and      are the absorbed dose, dose rate at time   and the cell repair rate, 
respectively. Please note that the   factor does not intrinsically depend on the 
administered activity   , even though it depends on the absorbed dose (Eq. (6)) and 
on the dose rate (Eq. (5)). From Eq. (8), the constant value    in the two components 
of  ̇    (Eq. (5)) can be taken out of the integrals as   
  in the numerator. This 
cancels out with the   
  in the denominator produced by    (Eq. (6)). 
For acute dose treatments (e.g. external-beam radiotherapy (EBRT)), the   factor is 
commonly assumed to be equal to 1. However, for prolonged dose treatments such 
as MRT, the   factor should be adequately computed for accurate SF calculations. 
Figure 6 illustrates the LQ model for an acute dose (   ) with its respective 
components for lethal and sub-lethal damage. 
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Figure 6. Representation of the linear-quadratic model. The lethal damage component (blue line) 
is proportional to the absorbed dose while the sub-lethal damage component (orange line) is 
proportional to the dose squared. The total biological effect (yellow line) considers both lethal and 
sub-lethal damage. The dashed black line divides the diagram in two regions: from 0 Gy to 3 Gy 
and higher than 3 Gy. In the first region, the lethal damage component prevails while in the 
second region the sub-lethal damage component produces the higher biological effect. This 
graph was created with values       Gy-1,       Gy-2 (    = 3 Gy) and    . 
 
Based on the LQ model, the BED (i.e. representation of dose accounting for the 
biological effect in a tissue) is defined as:  
      (  
 
   
  )    
      
 
      (9) 
where the ratio     is commonly used to represent the sensitivity of a particular 
tissue to a particular type of ionising radiation (i.e. radiosensitivity). Although the 
values for α and β should ideally be known to correctly describe the SF based on the 
absorbed dose using the LQ model, it is common to find in the literature only values 
for the ratio     (in units of [Gy]) as the parameter representing the radiosensitivity of 
different tissues. Given Eq. (8), the same absorbed dose produces different BED 
values in tissues with different radiosensitivity [53]. Therefore, BED is usually 
presented in units of [     ] (e.g. for a tissue with a ratio     of 10 Gy, the BED is 
presented in units of [Gy10]). 
BED values are mainly used to compare different radiation schemes (especially 
including fractionation (i.e. partition of the treatment in multiple fractions)) within a 
framework of isoeffective doses [53, 60]. However, because of the exponential 
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relationship between BED and SF (Eq. 9) (and therefore between BED and number 
surviving cells), comparisons and numerical operations (e.g. summation of radiation 
effects) using BED values are to be carefully and individually analysed. 
Although absorbed doses are still more often used than BEDs for radiotherapy 
treatment planning and treatment evaluation, BED values have recently gained 
attention especially in MRT treatment assessment. 
 
2.5  Treatment Planning in MRT 
Treatment planning in molecular radiotherapy comprises [7]: 
 Selection of the appropriate radiopharmaceutical  
 Determination of the activity to administer. 
 Determination of the amount of pharmaceutical to administer. 
 Evaluation of the use of additional pharmacokinetics-favouring substances. 
 Determination of the administration schedule (i.e. the start and end of each 
administration). 
The radionuclide and administration schedule to use are commonly defined based on 
the malignancy to treat and as a result of a clinical trial (or multiple clinical trials) in 
which the therapeutic effectiveness of the radiopharmaceutical and the side effects 
produced by the radiopharmaceutical under an specific administration schedule are 
considered [7]. Traditionally, treatment planning in MRT has been performed by only 
determining the activity to administer using a fixed administration schedule for a 
defined radiopharmaceutical without considering the pharmaceutical amount, which 
has been commonly neglected as a treatment-modulation factor [7, 62]. Thus, the 
pharmaceutical amount has routinely been determined by the specific/molar activity 
achieved in-situ during the radiopharmaceutical synthesis for the planned activity. 
The low relevance given to the pharmaceutical amount in MRT over the years is 
evidenced by the fact that only the administered activity (and not the pharmaceutical 
amount or the specific/molar activity) is reported in most MRT publications. However, 
it has been recently demonstrated that the pharmaceutical amount is an import 
treatment modulator as it changes the relative pharmacokinetics between the OARs 
and the target tissue (e.g. the tumour) allowing potential improvement of the 
therapeutic index [4, 17, 19]. Therefore, the pharmaceutical amount (and possibly the 
administration schedule) needs to be considered for adequate treatment planning in 
MRT [4].  
The importance of using pharmacokinetics-favouring substances (unlabelled 
pharmaceutical or other nonradioactive substances, e.g. amino acids) for treatment 
planning in MRT has also been demonstrated [63, 64]. These kinds of substances 
are administered to exploit the pharmacokinetic differences between the OARs and 
the target tissue. For instance, some organs/tissues have a faster uptake of a 
nonradioactive substance than the tumour lesions. As such, an early acute load of 
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this nonradioactive substance can be used to saturate the OAR receptors before the 
radioactive administration hence reducing the OAR radiopharmaceutical uptake [63, 
64]. Pharmacokinetics-favouring substances can be administered before (i.e. 
preload) or simultaneously with (i.e. co-infusion) the radiopharmaceutical. Infusions of 
pharmacokinetics-favouring substances starting before and continuing during the 
radiopharmaceutical administration are also used in practice (e.g. in PRRT, a 4-hour 
infusion of an amino acid solution is routinely administered 30 min before the start of 
the radiopharmaceutical infusion to reduce the radiopharmaceutical accumulation in 
the kidneys [35]). However, the application of pharmacokinetics-favouring substances 
may also reduce the accumulation of radiopharmaceutical in the target tissue, and 
therefore adequate planning is required before their administration.  
Different methods for treatment planning are used in MRT, which vary in complexity, 
costs, level of individualisation and outcomes [7]. According to the level of 
individualisation, two main categories of treatment planning methods exist in MRT: 
cohort-based and patient-based [7].  
In cohort-based treatment planning, the applied therapeutic plan (i.e. activity to 
administer, pharmaceutical amount and administration schedule) is determined by a 
previous study (e.g. a clinical trial) in which high standards of safety and efficacy are 
adopted [7]. In cohort-based studies, as in chemotherapy, the dosage (i.e. activity 
and/or pharmaceutical amount) to administer is determined by step-wise dosage 
escalation for a specific group of patients until reaching a mean incidence of a 
defined maximum tolerated toxicity [7, 62]. The dosage resulting from a cohort-based 
study can be further adapted based on patient characteristics such as body weight, 
disease stage or count of erythrocytes [7]. However, as there are inter-individual 
physiological differences and the patient-specific pharmacokinetics is not considered 
(low level of individualisation), the cohort-based approach can lead to under- and 
over-dosage [7, 16].  
In contrast to the cohort-based approach, in patient-based treatment planning the 
patient-specific pharmacokinetics is considered to individually determine the 
treatment plan to use (higher level of individualisation) [7]. Typically, patient 
pretherapeutic quantitative data (e.g. series of PET images) for the same or a similar 
radiopharmaceutical or data from a previous MRT treatment are used to determine 
patient-specific pharmacokinetics [7, 62]. A basic approach of patient-specific 
treatment planning is dosimetry-based treatment planning (DBTP), in which individual 
dosimetric calculations for the main OARs and the target are considered to determine 
the activity to administer [62]. For some fractionated treatments (treatments with 
multiple fractions (i.e. cycles)), the dosimetry-based approach consists in delivering 
cycles with a fixed activity until a specified dose limit (absorbed dose or BED) for the 
OARs is reached [62, 65]. In DBTP only the activity to administer (and not the 
pharmaceutical amount or the administration schedule) can be included in the 
planning process. Thus, accurate results using DBTP may only be achieved when 
the pharmaceutical amounts and administration schedules for the planning 
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administration and the therapeutic administration are similar. A more sophisticated 
approach of patient-specific treatment planning is based on patient-specific 
pharmacokinetic parameters and pharmacokinetic models (e.g. PBPK models) [7]. A 
general description of the pharmacokinetic-model-based treatment planning 
approach is given in Figure 7 [7]. 
 
 
Figure 7. Algorithm for pharmacokinetic-model-based treatment planning in molecular 
radiotherapy (modified from Glatting et al. [7]). 
 
MRT treatment planning based on individualised pharmacokinetic models (including 
PBPK models) consist in six well-defined steps [7]: 
1. Quantification of patient-specific pharmacokinetics using pretherapeutic 
quantitative data. Quantitative data can be used to validate a pharmacokinetic 
model and/or to individually estimate unknown pharmacokinetic parameters. 
2. Definition of individual pharmacokinetic parameters. These parameters can be 
measured, estimated or defined based on well-founded assumptions. 
Allometric scaling is commonly used to estimate unknown pharmacokinetic 
parameters. In addition, pharmacokinetic parameters can be estimated by 
fitting a validated pharmacokinetic model to individual quantitative data. 
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3. The individualised pharmacokinetic model is adapted to therapy conditions 
(e.g. by changing the nuclide half-life and/or the radiopharmaceutical amount) 
and simulations/estimations of pharmacokinetics for therapy are performed.  
4. Absorbed doses for the OARs and target region are calculated using the 
simulated pharmacokinetics. 
5. The treatment is planned based on the calculated absorbed doses and 
considering potential additional absorbed dose/BED restrictions for the OARs. 
Simulations of pharmacokinetics varying the treatment conditions (i.e. amount, 
activity and administration schedule) followed by new dose calculations are 
performed until optimal/acceptable characteristics for therapy (i.e. planned 
treatment) are achieved [4, 17, 18, 64]. 
6. The planned treatment is applied and additional measurements for quality 
control are performed. These measurements are used to verify treatment 
effectiveness and OAR toxicity and can also be utilised to improve the 
pharmacokinetic model for subsequent therapy cycles. 
For each therapeutic cycle the full treatment planning algorithm (as described above) 
should be applied.  
As treatment planning based on pharmacokinetic models uses a mechanistic 
approach, not only the activity but also the pharmaceutical amount, the administration 
schedule and the use of pharmacokinetics-favouring substances can potentially be 
planned depending on the used pharmacokinetic model [4, 64]. 
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3 MATERIALS AND METHODS 
In this chapter, the developed concepts of overall biologically effective dose (oBED) 
and overall tumour control probability (oTCP) are presented. The concept of virtual 
patients is also introduced and the characteristics of the virtual patients (including the 
description of the used PBPK model) considered in the conducted in silico clinical 
trial are given. The main part of this section is the description of the workflow of the 
developed treatment planning algorithm [66]. Lastly, the parameters used in the 
simulations performed in the in silico clinical trial are presented. 
An overview of relevant abbreviations used in this section and their respective 
definitions are presented in Table I. 
 
Table I. Relevant abbreviations for the developed treatment planning algorithm. 
Abbreviation Full form Meaning 
CLAAC Combined limiting 
amount-activity curve 
LAAC resulting from considering all the constraints for the 
organs at risk and for the radiopharmaceutical. 
LAAC Limiting amount-
activity curve 
Curve representing the maximum tolerated or achievable 
activity for each peptide molar amount. It can be based on 
an organ biologically effective dose constraint (maximum 
tolerated activity) or on a radiopharmaceutical constraint 
(maximum achievable activity). 
MA Molar activity Ratio between activity [Bq] and peptide amount [mol]. 
oBED Overall biologically 
effective dose 
Biologically effective dose representing organs/tissues 
with inhomogeneous characteristics or distribution (e.g. 
multiple tumour lesions). 
oSF Overall survival 
fraction 
Total survival fraction considering a group of tumour 
lesions. 
oTCP Overall tumour control 
probability 
Probability of achieving tumour control considering a 
group of tumour lesions. 
 
 
3.1 Overall Biologically Effective Dose 
The efficacy of a therapeutic plan in molecular radiotherapy or in any other cancer 
treatment depends on the number of killed/sterilised tumour cells. Nevertheless, it is 
common practice to determine the outcome of a radiotherapy treatment based on the 
tumour absorbed dose or BED for individual lesions. For patients with multiple tumour 
lesions, maximising the combined summation of the absorbed doses or BEDs in the 
lesions does not guarantee an optimal plan, unless all lesions have the same number 
of cells. This is because of the exponential relationship between the survival fraction 
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(SF) and the absorbed dose or BED and due to differences in the number of tumour 
cells between the lesions as shown in Eq. (10) 
   
      
      
                     
 
          (10) 
where SF in the survival fraction,        is the number of surviving cells,        is the 
total number of cells before irradiation, G is the Lea-Catcheside factor [60],   is the 
absorbed dose and   and   are the linear and quadratic parameters of the linear-
quadratic (LQ) model. 
Based on Eqs. (9) and (10), the total number of surviving tumour cells after irradiation 
considering multiple lesions can be expressed as: 
         ∑         
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)         (12) 
where          is the total number of surviving cells for all the considered lesions,   is 
the number of considered lesions,          is the number of surviving cells for each 
considered lesion,          is the initial number of tumour cells for each lesion,    and 
   are the linear and quadratic parameters of the LQ model for each lesion and     , 
   and    are the BED, the absorbed dose and the Lea-Catcheside factor for each 
lesion, respectively. 
Eqs. (11) and (12) can also be expressed in terms of the mass and the cell density of 
the considered tumour lesions as follows: 
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where    and    are the mass and the cell density of each tumour lesion, 
respectively.  
From Eqs. (13) and (14), the overall survival fraction (oSF) can be derived as: 
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where        is the total number of tumour cells among all the considered lesions. 
Based on Eq. (9), oSF can be converted into an overall BED (oBED) as follows: 
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where   is an overall linear parameter of the LQ model representing all the 
considered lesions. As presented in Eq. (18), the tumour oBED represents a BED 
accounting for the total surviving tumour cells (or clonogenic tumour cells) in the 
selected lesions. Note that for a single lesion the oBED is identical to the BED. 
The value of   in Eq. (18) is defined (Eq. (27)) such as the total number of surviving 
cells is equal when using the oBED with the overall   value and when individual 
BEDs (    ) and   values (  ) are considered for every lesion, as shown in Eq. (19): 
                    
         ∑             
                (19) 
As   and      are interdependent in Eq. (19), a single   value cannot be derived. 
To solve this interdependence, a first order Taylor expansion was used to make 
approximations of these expressions as presented from Eq. (20) to Eq. (26). 
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Then, Eq. (24) can be derived from Eq. (19), Eq. (21) and Eq. (23). 
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In case that all      =      and that for all lesions         << 1, it follows: 
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Considering the individual tumour masses and tumour cell densities, Eq. (26) can be 
written as: 
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Assuming the same    parameter ( ),     parameter ( ) and tumour cell density ( ), 
Eq. (17) and Eq. (18) can be simplified to: 
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Maximising the oBED as defined in this work leads to maximising the number of killed 
tumour cells among the considered tumour lesions. 
 
3.2 Overall Tumour Control Probability 
The relationship between radiation and cell survival is stochastic (i.e. described by a 
probabilistic model) [67]. Therefore, the effectiveness of a radiotherapy treatment is 
also stochastic. The probability of achieving an effective treatment of a tumour lesion 
is called tumour control probability (TCP) and depends on the number of surviving 
tumour clonogenic cells (i.e. cells able to proliferate). Therefore, TCP is commonly 
defined based on the survival fraction of the tumour clonogenic cells after 
radiotherapy treatment as follows [68]: 
                         (30) 
where     is the initial number of tumour clonogenic cells (i.e. clonogens) and SF is 
the survival fraction of the tumour clonogens after irradiation. Thus, for multiple 
tumour lesions and based on the developed concept of overall survival fraction (oSF), 
the overall tumour control probability (oTCP) can be defined as: 
                          (31) 
From Eq. (31), the oTCP for multiple cycles can be estimated as:   
           (
∏     
   
    )        (32) 
where     is the initial number of tumour clonogenic cells,    is the number of cycles 
and      is the overall SF for a particular cycle  . Eq. (32) can be used under the 
assumptions that (1) there is no or negligible tumour repopulation between cycles, (2) 
the number of tumour clonogens is large, (3) cell survival is a rare occurrence and (4) 
cell death is stochastically independent of other cells [69]. 
If the oSF is assumed equal for all the cycles, Eq. (32) can be simplified to: 
           (    
  )         (33) 
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Eq. (32) and Eq. (33) are valid for tumours with doubling times (i.e. time needed to 
double the tumour size) much longer than the typical time between treatment cycles. 
This is the case for NETs (doubling time between 2.3 years and 3.7 years [70]) and 
meningioma (doubling time of 4.5 years [71]), which are usually treated with PRRT 
(common time between cycles from 6 weeks to 16 weeks [72]).  
Complete treatment plans (i.e. including all the planned cycles) aim at achieving 
probabilities of having less than 1 tumour clonogen (TCP<37 %). However, adequate 
tumour control can be only defined for treatments producing at least 90 % TCP [68], 
with some authors defining adequate tumour control only for TCP values higher than 
99 % [73].  
 
3.3 Virtual Patients 
A virtual patient is a computationally implemented mathematical model used to 
simulate different scenarios for real patients [74]. In this work, a virtual patient was 
defined as a whole-body PBPK model fitted to individually measured 111In-
DOTATATE data from a patient with metastasising neuroendocrine tumours (NETs) 
or meningioma. Nine virtual patients were created and used for the conducted in 
silico clinical trial. To perform simulations with 177Lu-DOTATATE, the virtual patients 
created for 111In-DOTATATE were adapted by changing the nuclide half-life in the 
PBPK model (67.3 h for 111In [75] and 159.5 h for 177Lu [76]). The same numbering 
was kept for the virtual patients and the measured patients (Table II) (e.g. the virtual 
patient VP1 was generated with measured data from patient P1). 
 
3.3.1 Patient Data 
Datasets from nine patients (men = 6, women = 3, age = (52 ± 22) years) with 
metastasising NETs (n = 5) or meningioma (n = 4) injected with 111In-DOTATATE 
were used to generate the virtual patients considered in the conducted in silico 
clinical trial. The patient datasets considered in this study were the same as used by 
Kletting et al. [4] (however, only the first cycle of each patient was considered here). 
Each patient dataset consisted of a planar whole-body scintigraphy series (anterior 
and posterior), a computerised tomography (CT) image, serum time-activity data and 
a measurement of the glomerular filtration rate (GFR) using 51Cr-EDTA.  
To generate pretherapeutic data, an intravenous infusion ((51 ± 8) min) of 
DOTATATE ((75 ± 10) nmol) labelled with 111In ((140 ± 14) MBq) was administered to 
the patients. To reduce the nonspecific uptake of 111In-DOTATATE in the kidneys, 
1,000 ml of a 2.5 % solution of amino acids (lysine and arginine) was co-administered 
over 2 h, starting 0.5 h before the infusion of the radiopharmaceutical. Planar 
scintigraphy images taken with a e.cam® gamma camera (Siemens, 
Erlangen, Germany) were acquired 2 h, 4 h, 1 d, 2 d and 3 d after the end of the 
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peptide infusion. Blood samples were taken 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 1 d, 
2 d and 3 d following the completion of the 111In-DOTATATE infusion. Activity 
concentrations in serum were measured using an Auto-γ-5003 gamma counter 
(CANBERRA PACKARD Central Europe GmbH, Schwadorf, Austria). ULMDOS [77] 
and NUKDOS [78] software packages were used to retrieve time-activity data from 
the scintigraphy images for the liver, kidneys, spleen, tumour lesions and whole body. 
Two tumour lesions were considered in each patient except in patients 2, 4 and 5, for 
whom only one lesion was found. Activity data for the RM could not be directly 
retrieved. CT images were used to individually determine the volumes of the liver, 
kidneys, spleen and tumour lesions for each patient. Patient characteristics are 
shown in Table II. 
 
Table II. Patient characteristics. 
Patient Tumour Sex 
Age 
(years) 
BW 
(kg) 
Tumour Volumes (ml) 
Lesion 1 Lesion 2 
P1 Men M 31 78 87 20 
P2 Men M 31 81 116 - 
P3 Men F 56 84 2 0.5 
P4 Men M 70 86 3 - 
P5 NET M 76 78 2520
a
 - 
P6
b
 NET F 33 71 4 30 
P7 NET M 73 80 111 23 
P8 NET F 83 57 13 2 
P9 NET M 78 69 3 5 
a 
Estimated tumour volume, VTU = VLiver_Total – VLiver_Total_Average where VTU is the tumour volume, 
VLiver_Total is the measured liver volume and VLiver_Total_Average is the average liver volume for a 
male of the same weight. This calculation was performed due to the very large size of the 
tumour. 
b 
Patient with splenectomy. 
Men, meningioma; NET, neuroendocrine tumour; BW, body weight. 
 
3.3.2 PBPK Model 
A 111In-DOTATATE whole-body PBPK model previously created and validated by 
Kletting et al. [4] was implemented and used as a basis for creating the nine virtual 
patients used to perform simulations of pharmacokinetics. This model individually 
considers peptide pharmacokinetics in the kidneys, liver, RM, spleen, gastrointestinal 
track, lungs, muscles, adrenal glands, prostate, bones, heart, brain, adipose tissue, 
skin, arteries, veins and in two tumour lesions. The rest of the organs and tissues are 
grouped as the remainder. The model incorporates physiological characteristics such 
as distribution, vascular permeability, specific binding, internalisation, degradation 
and excretion. Two parallel systems constitute the model: labelled and unlabelled 
peptide [79]. These systems are linked by the physical decay of the radionuclide and 
compete for the available targeted receptors in the organs in a nonlinear interaction 
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[79]. Substance transfer among the organs is determined by the organ vascular 
volumes and blood flows. A scheme of the used PBPK model is presented in Figure 
5 (section 2.3). 
The described model was implemented in SAAM II (version 2.2, The Epsilon Group, 
Washington, USA) [50], where individualised PBPK model parameters were 
determined for each patient by fitting the model parameters to the patient 
pharmacokinetic data allowing to create virtual patients for 111In-DOTATATE [4, 19]. 
The fitting process considered patient-specific measured or scaled anatomical and 
physiological data as well as measured 111In-DOTATATE pharmacokinetic data both 
of the respective patient and of other patients [4, 19].  
The 111In-DOTATATE virtual patients were subsequently adapted to 177Lu-
DOTATATE by changing the physical decay parameter (nuclide half-life of 67.3 h for 
111In [75] and of 159.5 h for 177Lu [76]). The adapted 177Lu-DOTATATE virtual 
patients were implemented in Matlab/Simulink® to ease the automation of the 
simulation process. Model parameters for the virtual patients are the same as in 
Kletting et al. [4], being the nuclide half-life (159.5 h for 177Lu) [76] the only changed 
parameter. The system of differential equations describing the used PBPK model 
was solved using SAAM II and the equations are described in the supplemental data 
in Kletting et al. [4]. 
177Lu-DOTATATE was selected for this in silico clinical trial because of the large 
amount of attention drawn to this substance over the last years. This 
radiopharmaceutical presents high affinity to the somatostatin receptor type 2 (sstr2) 
and has a maximal penetration depth of 1.7 mm, which permits a more localised 
treatment (i.e. less collateral damage) than with 90Y-labelled radiopharmaceuticals 
(maximum penetration depth of 11 mm) [3, 5]. Moreover, 177Lu-DOTATATE has 
shown high effectiveness and safety, producing lower toxicity in kidneys and RM than 
other therapeutic substances (e.g. 90Y-DOTATOC), and, in addition, allows post-
therapy imaging [3, 5, 80]. 
 
3.4 Description of the Developed Treatment Planning Algorithm  
The aim of treatment planning in molecular radiotherapy, after specifying the 
radiopharmaceutical and administration schedule to use, is to determine the 
combination of substance amount and activity yielding the maximum tumour cell 
sterilisation while avoiding high toxicity in the OARs [4, 7]. Thus, the maximum 
feasible tumour dose will be constrained by the maximum tolerated doses for the 
main OARs. The maximum achievable MA (proportional to the maximum achievable 
specific activity) of the radiopharmaceutical is an additional restriction for the 
achievable combinations of radiopharmaceutical amount and activity. Therefore, both 
dose constraints for the potentially dose-limiting organs and synthesis limitations of 
the radioactive drugs are to be considered in the treatment planning process in 
molecular radiotherapy. 
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Based on the work of Kletting et al. [4], a new treatment planning method to patient-
specifically determine the optimal peptide amount and activity in PRRT was 
developed and implemented. This method, grounded on PBPK models, 
simultaneously considers the therapeutic effect in multiple tumour lesions, BED 
constraints for all the potentially dose-limiting organs and radiopharmaceutical 
synthesis limitations. 
The workflow consists of two main phases: 
1. An optimal activity (i.e. maximum activity) is calculated for each considered 
amount of radiopharmaceutical based on BED constraints for the potentially 
dose-limiting organs and on a radiopharmaceutical constraint (i.e. the 
maximum achievable MA). 
2. The combination of amount and activity leading to the highest tumour oBED is 
selected as the optimal combination to administer.  
Figure 8 illustrates the overall workflow of the developed treatment planning method. 
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Figure 8. Workflow of the developed treatment planning algorithm. Tilted parallelograms 
represent inputs or outputs of a process while rectangles represent processes [81]. First, based 
on individual patient data a virtual patient is created to perform simulations of pharmacokinetics 
using different amounts of peptide. From the simulations of pharmacokinetics, time-integrated 
activity coefficients (TIACs) and G factors (Eq. (8)) are calculated for the OARs and tumour 
lesions. These parameters, together with the dose factors (also called S values), the OAR α/β 
ratios and the specified maximum tolerated BEDs for the OARs are used to determine the 
maximum activities for each amount of peptide for each OAR (Eq. (37)). Maximum activities for 
each peptide amount are also calculated based on the maximum molar activity (MA) achievable 
during the radiopharmaceutical synthesis. Then, limiting amount-activity curves (LAACs) for each 
OAR and for the radiopharmaceutical are generated, with which the combined limiting amount-
activity curve (CLAAC) is determined. The tumour overall BED (oBED) is calculated (Eq. (28)) for 
each point (amount, activity) in the CLAAC. The point on the CLAAC leading to the maximum 
tumour oBED is determined as the optimal amount and the optimal activity to administer to the 
respective patient. 
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First, a virtual patient is created based on the individual patient pharmacokinetic data 
and implemented in a program which supports numerical differentiation/integration 
and that, preferably, allows simulations varying the administered peptide amount in 
an automated way (e.g. Matlab/Simulink®). Maximum tolerated BEDs for each 
potentially dose-limiting OAR are determined. A maximum achievable 
radiopharmaceutical MA is also specified. Simulations are then performed for multiple 
peptide amounts within a range of interest, by preference using geometric step sizes 
(i.e. using a constant multiplication factor). For each simulated peptide amount, a 
maximum tolerated activity is calculated for each OAR. The equation used to 
calculate the maximum tolerated activity for a specific peptide amount for each OAR 
(Eq. (37)) is based on the maximum tolerated OAR BED and is derived from Eq. (6) 
and Eq. (9) as presented from Eq. (34) to Eq. (37): 
Eq. (9) can be rewritten as: 
  
 
   
                   (34) 
Solving the quadratic equation for   in Eq. (34) results in: 
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The second solution of the square root is not used for the further calculations as the 
absorbed dose cannot have negative values and   and     are always positive 
values. 
Inserting Eq. (6) in Eq. (35), assuming BED as the maximum tolerated OAR BED 
(and therefore representing the maximum tolerated OAR absorbed dose and the 
maximum tolerated administered activity     ) results in: 
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and after solving for      we obtain: 
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where      is the maximum tolerated activity for the OAR for a specific peptide 
amount,  is the number of organs/tissues considered in the dose calculations, 
 ̃      is the TIAC in each organ/tissue considered in the dose calculations for a 
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specific peptide amount,          is the dose factor between each considered organ 
and the OAR,   is the Lea-Catcheside factor (which is independent from the 
administered activity) for the OAR for a specific peptide amount,   and   are the 
linear and quadratic parameters of the LQ model for the OAR, and        is the 
maximum tolerated OAR BED. 
The calculated maximum tolerated activities for each amount define the limiting 
amount-activity curve (LAAC) for each OAR, such as every point in a LAAC 
represents an organ BED equal to its maximum tolerated dose (Figure 9). A LAAC is 
also generated for the radiopharmaceutical according to the maximum MA 
achievable during synthesis (Figure 9). Subsequently, a combined limiting amount-
activity curve (CLAAC) is determined considering the minimum activity for each 
amount among all the LAACs (i.e. OARs plus radiopharmaceutical) (Figure 9). Thus, 
the CLAAC determines the maximum activity, and therefore the maximum tumour 
absorbed dose or BED, that can be administered for each peptide amount 
considering dose constraints for the OARs and limitations of the radiopharmaceutical 
synthesis. In addition, the region lying below the CLAAC represents all the 
achievable combinations of amount and activity accounting for the mentioned 
constraints (Figure 9). 
 
 
Figure 9. Limiting amount-activity curves. LAACs for kidneys (solid blue line), RM (dashed red 
line) and radiopharmaceutical (RPh.) (dotted black line) and definition of the CLAAC (bold dashed 
black line). The region of achievable combinations of amount and activity leading to tolerated 
OAR BEDs is below the CLAAC. This graph was produced by applying the described treatment 
planning algorithm to simulations for the virtual patient VP1. The maximum tolerated BEDs for the 
kidneys and RM were 10 Gy2.5 and 0.5 Gy15 per cycle, respectively. The maximum MA for 
177
Lu-
DOTATATE was determined by the highest practical MA reported in the literature that is 420 
MBq/nmol [25]. 
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To determine the optimal plan, tumour oBEDs are calculated (Eq. (17) or Eq. (28)) for 
each point (amount, activity) of the CLAAC. Considering tumour oBEDs instead of 
individual tumour BEDs allows to obtain a unique optimal plan for patients with 
multiple tumour lesions. Thereafter, the point in the CLAAC yielding the maximum 
tumour oBED (representing the maximum number of killed tumour cells among the 
considered lesions) is determined as the optimal amount and activity to administer to 
the patient for a respective cycle (Figure 10). 
 
 
Figure 10. Determination of the optimal amount and activity. Top: definition of the CLAAC (bold 
dashed black line) and optimal point (amount, activity) in the CLAAC (circle); the abscissa axis 
corresponds to the total amount of substance and was not written to simplify the diagram. Bottom: 
tumour oBED curve (solid line) indicating the maximum tumour oBED accounting for the specified 
constraints (circle). The points of the tumour oBED curve were calculated with the combinations 
of amount and activity defined by the CLAAC. The dash-dot bold red line connecting the bottom 
and top diagrams links the maximum tumour oBED (bottom circle) with the combination of 
amount and activity which produces it (top circle). The graphs in this figure correspond to 
applying the described method to simulations for the virtual patient VP1. The same parameters as 
in Figure 9 were used. 
35 
 
3.5 In Silico Clinical Trial 
The developed 177Lu-DOTATATE virtual patients were implemented in 
Matlab/Simulink® (MathWorks, Natick, Massachusetts, USA) to perform simulations 
of pharmacokinetics for different amounts of peptide. For each virtual patient, 
simulations were performed varying the peptide amount from 2 nmol to 2048 nmol in 
geometric step sizes of √ 
 
 (51 different amounts) for a fixed infusion time of 30 min 
[72, 82]. For each amount, 1000 h of therapy time (> 6 half-lives of 177Lu [76]) were 
simulated using the Accelerator mode in Simulink®. Maximum cumulative tolerated 
BEDs for the kidneys (40 Gy2.5 [83]) and for the RM (2 Gy15 [4, 84]) were assumed. A 
total of 4 PRRT cycles were assumed for the completion of the treatment [3, 72, 80], 
leading to maximum tolerated BEDs per cycle of 10 Gy2.5 and 0.5 Gy15 for the 
kidneys and the RM, respectively. The highest practical MA reported in the literature 
for 177Lu-DOTATATE (420 MBq/nmol [25]) was used as radiopharmaceutical 
synthesis constraint. To calculate the absorbed doses in the OARs, dose factors 
(also called S values) for 177Lu were extracted from OLINDA/EXM [44], while dose 
factors for the tumour lesions were estimated based on their masses [85] (Appendix 
A, Table A - I). For BED calculations, α/β ratios of 2.5 Gy were assumed for kidneys, 
liver and spleen, and of 15 Gy and 10 Gy for the RM and the tumour lesions, 
respectively [4, 86, 87]. Moreover, repair rates μrep of ln(2)/2.8 h
-1 were used for the 
kidneys, liver and spleen [14], and of ln(2)/1.0 h-1 and ln(2)/1.5 h-1 for the RM [88] and 
the tumour lesions [89], respectively. An   value of 0.35 Gy-1 was used for all tumour 
lesions [86] to calculate the oBED (Eq. (17)). Tumour lesions were assumed to have 
the same cellular density ( ) and radiosensitivity ( ) (Eq. (17)). 
The maximum activities accounting for the specified kidney and RM tolerated BEDs 
were calculated for each simulated amount using Eq. (37). The maximum achievable 
activity for each peptide amount was also determined for each virtual patient based 
on the radiopharmaceutical synthesis limitation. After simulating all the included 
amounts, the LAACs for the kidneys, RM and radiopharmaceutical were created and 
the CLAAC was defined for each virtual patient. The tumour oBED (Eq. (28)) was 
calculated for each combination of amount and activity defined in the CLAAC for 
each virtual patient. The maximum tumour oBED in the CLAAC determined the 
optimal amount and activity to administer to each virtual patient. BEDs (Eq. (9)) for 
the kidneys, RM, liver, spleen and individual tumour lesions were calculated for each 
virtual patient with the optimal amount and activity. Individual and overall SFs for the 
tumour lesions were also computed for the optimal plans.  
For comparison purposes, simulations using the developed 177Lu-DOTATATE virtual 
patients were also performed for a typically administered combination of amount (265 
nmol) and activity (7.4 GBq) per cycle [72, 90]. BED and SF calculations for the 
typical plan were carried out in the same manner as for the optimal plans. oTCP 
values (Eq. (33)) were also estimated for one, two, three and four cycles of treatment 
for the optimal and typical plans. 
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Complete treatment plans (i.e. including the four planned cycles of 177Lu-DOTATATE) 
leading to an oTCP equal to or higher than 99 % [73] were defined in this in silico 
clinical trial as plans producing adequate tumour control. 
The simulation time of each completed treatment planning process was registered 
(processor: Intel® Core™ i7-4790 @ 3.60 GHz, RAM: 16 GB, 64 bits). 
 
3.6 Data Analyses and Statistics 
Mean and standard deviation (SD) values are presented for descriptive statistics. 
Maximum, minimum and median values were calculated to present ranges and 
typical values.  
The Rosenbrock method for stiff differential equations was used in the simulations 
with Simulink® to solve the PBPK model equations and to perform other 
integral/derivative calculations. Variable time steps not longer than 30 min and with a 
maximum calculation error of 0.1 % per step were set in the Simulink® solver for all 
the simulations.  
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4 RESULTS 
The resulting optimal amounts and activities obtained by applying the developed 
treatment planning algorithm (section 3.5) to the created virtual patients for the 
defined constraints are shown in Table III. 
 
Table III. Optimal amounts and activities and BEDs and absorbed doses for the OARs and 
tumour lesions for the optimal plans. Results were obtained using the nine created 
177
Lu-
DOTATATE virtual patients and simulating injections of different peptide amounts. 
Virtual 
patient 
(Tumour) 
Amount 
[nmol] 
Activity 
[GBq] 
oBEDTU 
[Gy]
a
 
BEDK [Gy2.5] 
(DK [Gy]) 
BEDRM [Gy15] 
(DRM [Gy]) 
BEDTU_1 [Gy10] 
(DTU_1 [Gy]) 
BEDTU_2 [Gy10] 
(DTU_2 [Gy]) 
VP1 (M) 64.0 8.9 9.2 10.0 (8.9)
b
 0.27 (0.27) 12.6 (12.3) 5.3 (5.2) 
VP2 (M) 97.0 12.1 17.6 10.0 (9.0)
b
 0.31 (0.31) 17.6 (17.0) - 
VP3 (M) 512.0 29.8 2.8 10.0 (9.0)
b
 0.49 (0.49) 2.2 (2.1) 18.9 (18.2) 
VP4 (M) 48.5 10.0 18.4 10.0 (8.4)
b
 0.25 (0.25) 18.4 (17.5) - 
VP5 (N) 73.5 9.0 106.7 5.8 (5.2) 0.50 (0.50)
 c
 106.7 (100.3) - 
VP6 (N)
d
 24.3 6.2 18.7 10.0 (8.6)
b
 0.25 (0.25) 12.6 (12.2) 33.7 (31.9) 
VP7 (N) 73.5 16.4 33.6 9.9 (8.6) 0.50 (0.50)
c
 52.0 (50.3) 28.6 (28.1) 
VP8 (N) 64.0 9.2 54.2 9.2 (8.3) 0.50 (0.50)
c
 53.8 (52.1) 106.8 (100.4) 
VP9 (N) 97.0 7.0 6.0 10.0 (8.6)
b
 0.31 (0.31) 7.1 (7.0) 5.8 (5.7) 
Median 73.5 9.2 18.4 10.0 (8.6) 0.31 (0.31) 17.6 (17.0) 23.8 (23.2) 
Min. 24.3 6.2 2.8 5.8 (5.2) 0.25 (0.25) 2.2 (2.1) 5.3 (5.2) 
Max. 512 29.8 106.7 10.0 (9.0) 0.50 (0.50) 106.7 (100.3) 106.8 (100.4) 
a
 Calculated with α = 0.35 Gy-1. 
b
 Dose-limiting organ. Kidney BED = 10 Gy2.5. 
c
 Dose-limiting organ. Red marrow BED = 0.5 Gy15. 
d
 Splenectomy. 
M, meningioma; N, neuroendocrine tumour; D, absorbed dose. 
Subscripts K, RM, TU, TU_1 and TU_2 stand for kidneys, red marrow, tumour, tumour lesion 1 
and tumour lesion 2, respectively. 
 
As shown in Table III, the optimal amount and activity ranged from 48.5 nmol to 
512.0 nmol (median 80.5 nmol) and from 8.9 GBq to 29.8 GBq (median 11.5 GBq) for 
virtual patients with meningioma, and from 24.3 nmol to 97.0 nmol (median 73.5 
nmol) and from 6.2 GBq to 16.4 GBq (median 9.0 GBq) for virtual patients with NETs. 
The median molar activity was 139 MBq/nmol ranging from 58 MBq/nmol (VP3) to 
257 MBq/nmol (VP6) (Appendix B, Table A - III). In all virtual patients with 
meningioma the kidneys were the dose-limiting organ while in 3 out of 5 virtual 
patients with NETs (VP5, VP7 and VP8) the optimal treatment reached the constraint 
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for the maximum RM BED. In none of the simulated cycles the specified maximum 
achievable radiopharmaceutical MA (420 MBq/nmol) was the dominant constraint. 
From all the performed simulations, the BED for meningioma lesions ranged from 2.2 
Gy10 to 18.9 Gy10 (median 15.1 Gy10) and from 5.8 Gy10 to 106.8 Gy10 (median 33.7 
Gy10) for NET lesions. Tumour oBED values for the optimal plans varied between 2.8 
Gy and 106.7 Gy (α = 0.35 Gy-1). The median liver and spleen BEDs were 1.8 Gy2.5 
(range 1.0 Gy2.5 to 3.8 Gy2.5) and 15.5 Gy2.5 (range 11.9 Gy2.5 to 25.9 Gy2.5), 
respectively (Appendix, Table A - III).  
The mean simulation time for applying the presented treatment planning method 
evaluating 51 potentially optimal amounts was (2.6 ± 0.1) min. 
Figure 11 shows the diagrams for determining the optimal amount and activity (left), 
and the BEDs for the tumour lesions calculated for every point of the CLAAC (right) 
for 2 representative virtual patients (VP1 and VP8). Values for the typical plan (stars) 
are also included in Figure 11. 
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Figure 11. Optimal amount and activity and BEDs for the tumour lesions calculated for every 
point of the CLAAC for two representative virtual patients (Left: VP1; Right: VP8). Top: graphs 
illustrating the developed treatment planning algorithm plus the typically administered amount and 
activity (red star) [72, 90]. For VP1 (meningioma) the treatment is limited by the maximum 
tolerated kidney BED while for VP8 (NET) the dose-limiting organ is the RM. Bottom: BED vs 
peptide amount curves for the tumour lesions calculated for every point of the CLAAC. The 
vertical red dashed line represents the optimal amount, which intercepts the tumour BED curves 
at the BED values for the tumour lesions 1 and 2 when the optimal plan is applied. The magenta 
and black stars represent the BED for the tumour lesions 1 and 2 for the typical plan, 
respectively. Tumour lesion masses were 87 g (lesion 1) and 20 g (lesion 2) for VP1, and 13 g 
(lesion 1) and 2 g (lesion 2) for VP8. Note that the tumour lesion with larger mass has a higher 
influence on determining the optimal plan. 
 
As shown in Figure 11 (top), the radiopharmaceutical synthesis determines the 
maximum activity (and therefore absorbed doses) for low peptide amounts; for 
intermediate amounts the kidneys are the dose-limiting organ, and for larger peptide 
amounts the RM is which limits the treatment. This same tendency was observed 
among all the virtual patients (graphs shown in Jiménez-Franco et al., supplement C 
[66]). What varied from virtual patient to virtual patient was the range of peptide 
amounts in which each of the constraints prevailed (for VP5 the kidneys did not limit 
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the treatment for any of the evaluated amounts). In addition, simulations of the 
typically delivered plan [72, 90] yielded results within the defined constraints for all 
the virtual patients (Table IV). The typical plan also produced considerably lower 
tumour BEDs than the optimal plans for the considered tumour lesions (Table III and 
Table IV). 
The results of a simulated cycle for the typically delivered plan (265 nmol, 7.4 GBq, 
30 min infusion) [72, 90] for the nine virtual patients are presented in Table IV. 
 
Table IV. BEDs and absorbed doses for the OARs and tumour lesions resulting from simulating 
the typically administered amount (265 nmol) and activity (7.4 GBq) (MA = 28 MBq/nmol) [72, 90] 
for the created 
177
Lu-DOTATATE virtual patients. 
Virtual 
Patient 
(Tumour) 
oBEDTU 
[Gy]
a
 
BEDK [Gy2.5] 
(DK [Gy]) 
BEDRM [Gy15] 
(DRM [Gy]) 
BEDTU_1 [Gy10] 
(DTU_1 [Gy]) 
BEDTU_2 [Gy10] 
(DTU_2 [Gy]) 
VP1 (M) 3.4 3.1 (3.0) 0.13 (0.13) 4.0 (4.0) 1.7 (1.7) 
VP2 (M) 5.3 3.0 (2.9) 0.14 (0.14) 5.3 (5.3) - 
VP3(M) 1.4 3.7 (3.6) 0.15 (0.15) 0.8 (0.8) 7.5 (7.4) 
VP4 (M) 4.7 2.5 (2.4) 0.11 (0.11) 4.7 (4.6) - 
VP5 (N) 65.4 3.3 (3.1) 0.39 (0.39) 65.4 (62.9) - 
VP6 (N)
b
 8.1 2.9 (2.8) 0.14 (0.14) 3.7 (3.7) 9.9 (9.8) 
VP7 (N) 9.2 1.9 (1.9) 0.19 (0.19) 10.6 (10.6) 6.1 (6.0) 
VP8 (N) 20.6 2.9 (2.8) 0.33 (0.33) 20.2 (19.9) 32.3 (31.7) 
VP9 (N) 3.4 5.4 (5.0) 0.27 (0.27) 4.0 (4.0) 3.3 (3.3) 
Median 5.3 3.0 (2.9) 0.15 (0.15) 4.7 (4.6) 6.8 (6.7) 
Min. 1.4 1.9 (1.9) 0.11 (0.11) 0.8 (0.8) 1.7 (1.7) 
Max. 65.4 5.4 (5.0) 0.39 (0.39) 65.4 (62.9) 32.3 (31.7) 
a
 Calculated with α = 0.35 Gy-1. 
b
 Splenectomy. 
M, meningioma; N, neuroendocrine tumour; D = absorbed dose. 
Subscripts K, RM, TU, TU_1 and TU_2 stand for kidneys, red marrow, tumour, tumour lesion 1 
and tumour lesion 2, respectively. 
 
The simulations of a typical plan yielded tumour BEDs from 0.8 Gy10 to 65.4 Gy10 
(median 5.3 Gy10) while the median BEDs for the kidneys and the RM were 3.0 Gy2.5 
(range 1.9 Gy2.5 to 5.4 Gy2.5) and 0.15 Gy15 (range 0.11 Gy15 to 0.39 Gy15), 
respectively. Tumour oBED values (α = 0.35 Gy-1) ranged from 1.4 Gy to 65.4 Gy 
with a median of 5.3 Gy. 
To compare the effectiveness of the optimal and the typically delivered plans, the 
tumour overall survival fractions (oSFs) (Eq. (15)) (as a representation of the total 
tumour cell killing/sterilisation) were calculated for each virtual patient after one, two, 
three and four PRRT cycles with 177Lu-DOTATATE (Table V). The total survival 
41 
 
fraction      after multiple cycles assuming the same survival fraction for each cycle 
can be calculated as: 
          
  
         (38) 
where      is the overall SF for a particular cycle (the first cycle in this work) and    
is the number of cycles. 
 
Table V. Progression of the oSF through the cycles (for a total treatment of 4 cycles) for the 
typical and optimal plans with 
177
Lu-DOTATATE. The oSFs for all the cycles were assumed equal 
to the oSF for the first cycle for the nine virtual patients. 
Virtual 
patient 
oSF after 1 cycle oSF after 2 cycles oSF after 3 cycles oSF after 4 cycles 
Typical Optimal Typical Optimal Typical Optimal Typical Optimal 
VP1 3.0×10
-1
 3.9×10
-2
 9.1×10
-2
 1.6×10
-3
 2.8×10
-2
 6.2×10
-5
 8.3×10
-3
 2.4×10
-6
 
VP2 1.6×10
-1
 2.1×10
-3
 2.4×10
-2
 4.5×10
-6
 3.7×10
-3
 9.4×10
-9
 5.8×10
-4
 2.0×10
-11
 
VP3 6.1×10
-1
 3.8×10
-1
 3.8×10
-1
 1.4×10
-1
 2.3×10
-1
 5.3×10
-2
 1.4×10
-1
 2.0×10
-2
 
VP4 1.9×10
-1
 1.6×10
-3
 3.7×10
-2
 2.6×10
-6
 7.1×10
-3
 4.2×10
-9
 1.4×10
-3
 6.8×10
-12
 
VP5 1.2×10
-10
 6.0×10
-17
 1.3×10
-20
 3.6×10
-33
 1.6×10
-30
 2.2×10
-49
 1.8×10
-40
 1.3×10
-65
 
VP6 6.0×10
-2
 1.4×10
-3
 3.6×10
-3
 2.1×10
-6
 2.1×10
-4
 3.0×10
-9
 1.3×10
-5
 4.3×10
-12
 
VP7 4.1×10
-2
 7.8×10
-6
 1.6×10
-3
 6.1×10
-11
 6.7×10
-5
 4.7×10
-16
 2.7×10
-6
 3.7×10
-21
 
VP8 7.4×10
-4
 5.7×10
-9
 5.5×10
-7
 3.3×10
-17
 4.1×10
-10
 1.9×10
-25
 3.1×10
-13
 1.1×10
-33
 
VP9 3.1×10
-1
 1.2×10
-1
 9.4×10
-2
 1.5×10
-2
 2.9×10
-2
 1.9×10
-3
 8.8×10
-3
 2.4×10
-4
 
Median 1.6×10
-1
 1.6×10
-3
 2.4×10
-2
 2.6×10
-6
 3.7× 0
-3
 4.2×10
-9
 5.8×10
-4
 6.8×10
-12
 
Min. 1.2×10
-10
 6.0×10
-17
 1.3×10
-20
 3.6×10
-33
 1.6×10
-30
 2.2×10-
49
 1.8×10
-40
 1.3×10
-65
 
Max. 6.1×10
-1
 3.8×10
-1
 3.8×10
-1
 1.4×10
-1
 2.3×10
-1
 5.3×10
-2
 1.4×10
-1
 2.0×10
-2
 
 
The comparison between the simulated optimal and typically delivered plans (Table 
V) shows that the optimal plans produced up to 6 orders of magnitude (VP5) smaller 
tumour oSFs (higher effectiveness at sterilising tumour cells) than the typical plan for 
the first cycle (24 orders of magnitude after 4 cycles). The tumour oSFs for the first 
177Lu-DOTATATE cycles for the optimal and the typical plans ranged from 6.0×10-17 
(VP5) to 3.8×10-1 (VP3) (median 1.6×10-3) and from 1.2×10-10 (VP5) to 6.1×10-1 
(VP3) (median 1.6×10-1), respectively.  
Assuming a tumour clonogenic cell density of 1.12×105 cells/g [91] and based on the 
calculated oSFs for a single cycle (Table V), overall tumour control probability (oTCP) 
values were estimated (Eq. (33)) after one, two, three and four cycles of treatment 
(Table VI). 
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Table VI. Progression of the oTCP through the cycles (for a total treatment of 4 cycles) for the 
typical and optimal plans with 
177
Lu-DOTATATE. The oSFs for all the cycles were assumed equal 
to the oSF for the first cycle. The total tumour mass is the summation of the masses of all the 
considered tumour lesions in each virtual patient. 
Virtual patient 
(Total tumour 
mass) 
oTCP after 1 cycle oTCP after 2 cycles oTCP after 3 cycles oTCP after 4 cycles 
Typical Optimal Typical Optimal Typical Optimal Typical Optimal 
VP1 (107g) 0.00
a
 0.00
a
 0.00
a
 0.00
a
 0.00
a
 0.00
a
 0.00
a
 2.17×10
-13
 
VP2 (116 g) 0.00
a
 0.00
a
 0.00
a
 7.56×10
-26
 0.00
a
 8.85×10
-1
 0.00
a
 1.00
b
 
VP3 (2.5 g) 0.00
a
 0.00
a
 0.00
a
 0.00
a
 0.00
a
 0.00
a
 0.00
a
 0.00
a
 
VP4 (3 g) 0.00
a
 0.00
a
 0.00
a
 4.16×10
-1
 0.00
a
 9.99×10
-1
 0.00
a
 1.00
b
 
VP5 (2520 g) 9.68×10
-1
 1.00
b
 1.00
b
 1.00
b
 1.00
b
 1.00
b
 1.00
b
 1.00
b
 
VP6 (34 g) 0.00
a
 0.00
a
 0.00
a
 3.81×10
-4
 0.00
a
 9.89×10
-1
 8.21×10
-22
 1.00
b
 
VP7 (134 g) 0.00
a
 1.71×10
-51
 0.00
a
 9.99×10
-1
 0.00
a
 1.00
b
 2.36×10
-18
 1.00
b
 
VP8 (15 g) 0.00
a
 9.90×10
-1
 3.94×10
-1
 1.00
b
 9.99×10
-1
 1.00
b
 1.00
b
 1.00
b
 
VP9 (18 g) 0.00
a
 0.00
a
 0.00
a
 0.00
a
 0.00
a
 0.00
a
 0.00
a
 0.00
a
 
a
 Values smaller than or equal to 1.0×10
-100 
b
 Values larger than or equal to 9.995×10
-1
 
 
According to the estimated oTCP values (Table VI), applying the optimal plans allows 
adequate tumour control (oTCP higher or equal to 99 %) in 6 out of the 9 virtual 
patients after 4 cycles of 177Lu-DOTATATE are administered. However, based on the 
results of the simulations, only in 2 virtual patients adequate tumour control was 
achieved after 4 cycles of the typical plan. 
BED results for the liver and the spleen after the first cycle of 177Lu-DOTATATE for 
the optimal and typical plans are presented in Table A - III (Appendix B). 
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5 DISCUSSION 
In this work an algorithm for individualised treatment planning in PRRT was 
presented and applied to simulations of pharmacokinetics with 177Lu-DOTATATE 
using nine virtual patients. To demonstrate the applicability and advantages of the 
developed algorithm, comparison was drawn between the optimal plans and the 
typically delivered plan using the same virtual patients.  
Although the algorithm presented by Kletting et al. [4] was a first step towards 
individualised treatment planning in molecular radiotherapy, the algorithm was not 
suitable for clinical practice.  To achieve clinical applicability, the algorithm presented 
in this work includes the following required enhancements and extensions: 
1. Consideration of multiple potentially dose-limiting organs (e.g. kidneys and 
RM) in the optimisation process.  
2. Incorporation of a radiopharmaceutical constraint (i.e. maximum achievable 
specific activity [MBq/µg] or molar activity [MBq/nmol]).  
3. Simultaneous consideration of all tumour lesions/metastases in the 
optimisation process by applying the developed concept of oBED.  
Incorporating these features allows to derive a unique optimal plan (i.e. optimal 
peptide amount and activity to be administered) which maximises the total number of 
killed tumour cells in the considered lesions. Moreover, these improvements enable 
to consider every OAR as a potentially dose-limiting organ and to ensure that the 
resulting optimal amounts and activities can actually be administered to the patients 
in a safe way. Thus, the developed algorithm is general, effective, flexible and a 
relevant clinically applicable approach. 
The presented algorithm uses the derived general equation for the oBED (Eq. (17)) to 
simultaneously consider multiple tumour lesions. This equation is a generalisation of 
the concept of equivalent uniform biologically effective dose (EUBED) presented by 
O’Donoghue [92] and by Cremonesi et al. [93]. The main difference between oBED 
(Eq. (17)) and EUBED is that Eq. (17) individually considers the radiation sensitivity 
(  ) and the cell density (  ) for each lesion. This allows to individually include 
specific tumour characteristics (e.g. tumour stage or tumour oxygen enhancement 
ratio) in calculations or in treatment planning. Other authors have previously used the 
term “overall biologically effective dose (OBED)” [94]. However, the definition of the 
concept greatly differs from the equation developed in this work as it was defined as 
an algebraic summation of BED values [94]. 
The concept of oBED can also be used to calculate the cumulated tumour BED after 
multiple PRRT cycles considering tumour changes between cycles (e.g. changes in 
tumour mass [95]). Moreover, Eq. (17) can be applied to estimate the total BED for 
distributed organs such as the RM. 
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The main limitation of the introduced concept of oBED (Eq. (17)) is the need for    
values, which are not commonly found in the literature, where   /   ratios are more 
frequently (but still rarely) given. An additional limitation of the oBED is that the 
general   value representing all the considered lesions (Eq. (27)) may pose a 
challenge to compare doses from different plans or studies, especially for tumour 
lesions with different    values. Therefore, comparison of treatments based on 
parameters such as the tumour control probability or the number of killed clonogenic 
tumour cells (or survival fraction) may lead to a broader consensus. 
A more general form of Eq. (17) could also be formulated using single or multiple 
integrals to account for inhomogeneous uptake, inhomogeneous cell density and/or a 
changing radiation sensitivity [96-99]. However, this is beyond the scope of this work. 
The results obtained for the typical plan with 177Lu-DOTATATE (Table IV) are in line 
with BED and absorbed dose values presented in the literature [65, 100, 101]. For 
the kidneys, more commonly performed dose calculations in PRRT, Sandström et al. 
obtained BED values (for the typical plan) ranging from 1.7 Gy2.6 to 11.6 Gy2.6 while 
the absorbed dose values ranged from 1.7 Gy to 9.8 Gy (right kidney) [100]. Sundlöv 
et al. obtained BED values from 2.3 Gy2.5 to 19.1 Gy2.5 and absorbed doses from 2.2 
Gy to 14.3 Gy [65]. For the red marrow, Sandström et al. obtained absorbed doses 
from 0.05 to 0.4 Gy for the typical plan but did not perform BED calculations (red 
marrow BED values are expected to be very close to the absorbed doses because of 
the low dose values and the high α/β value) [101]. These results are also in line with 
the results presented in Table IV.  
The highly variable patient-specific optimal amounts (from 24.3 nmol to 512.0 nmol) 
and activities (from 6.2 GBq to 29.8 GBq) obtained in the conducted in silico clinical 
trial show the necessity of considering individual pharmacokinetics in treatment 
planning in MRT (e.g. using PBPK models). Individualised treatment planning may 
allow to safely increase the administered activity within controlled ranges of toxicity 
for the OARs while producing a higher tumour control [7], as shown in Table VI. 
Furthermore, Table VI shows that the typical plan may be insufficient to produce 
adequate tumour control after a 4-cycle treatment with 177Lu-DOTATATE while the 
optimal plans may produce adequate tumour control for most patients (6 out of 9 
virtual patients).  
As shown in Table III, the developed optimisation algorithm leads, in general, to lower 
peptide amounts and higher activities than the typically applied 177Lu-DOTATATE 
cycle. This implies a need for using higher molar activities than those routinely used 
to obtain more effective 177Lu-DOTATATE PRRT treatments. In addition, the fact that 
both the kidneys and the RM were the dose-limiting organs for different virtual 
patients indicates that these two organs need to be considered in treatment planning 
for PRRT. This also confirms the importance of performing accurate dosimetry for 
these organs [45, 102].  
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In the conducted in silico clinical trial, the assumed radiopharmaceutical constraint for 
177Lu-DOTATATE (420 MBq/nmol) was never the dominant constraint in the 
treatment planning process when using the developed algorithm. However, this molar 
activity is the highest reported in the literature for 177Lu-DOTATATE [25]. Thus, 
considerably lower molar activities are routinely achieved for 177Lu-DOTATATE (e.g. 
60 MBq/nmol [103], 38 MBq/nmol [104] and 28 MBq/nmol [72, 90]). Therefore, 
assuming a routinely achieved molar activity (or any other maximum achievable 
molar activity lower than 420 MBq/nmol) in the optimisation process will change the 
derived optimal plans. This will be explored in future work. 
The median liver and spleen BED values obtained with the optimal plans are 
approximately triple the median BED values for these organs when the typical plan is 
applied (Appendix B, Table A – III). However, the median tumour BED value for the 
optimal plans are approximately quadruple the tumour BEDs produced by the typical 
plan (Table III and Table IV). This leads in general to achieve higher therapeutic 
indices considering these organs when the optimal plans are delivered. The 
considerably higher BED values for the liver and the spleen for the optimal plans may 
indicate that these organs need to be included as potentially dose-limiting organs in 
the treatment planning algorithm (maximum tolerated BED values need to be 
determined). 
Comparison between the tumour BEDs for the optimal and typically delivered plans 
could be drawn from Table III and Table IV. However, BED differences should be 
carefully and individually analysed because of the nonlinear relationship between the 
BED and the survival fraction. Therefore, comparison of the tumour BED values was 
not performed in this work. 
Applying the developed algorithm may also result in economic benefits represented 
in less peptide amount per patient and less number of cycles because of the 
increased tumour sterilisation. 
The presented treatment planning algorithm can also be used for other therapies 
using radiolabeled ligands (e.g. radioimmunotherapy) [4, 17-19, 105]. Moreover, as 
the algorithm is based on PBPK model, it can additionally include the optimisation of 
the administration schedule which may also consider the use of additional 
substances for modulation of individual pharmacokinetics (e.g. preload) [7]. 
To be clinically applied, the developed algorithm requires an individualised PBPK 
model (i.e. a virtual patient). Individualisation of the 177Lu-DOTATATE PBPK model 
for the first cycle can be achieved with at least one data point of a quantitative 
pretherapeutic imaging modality (e.g. SPECT or PET) [16]. For subsequent 177Lu-
DOTATATE cycles, images from a previous cycle can be used to individualise the 
model as there may be inter-cycle changes (e.g. in tumour size). If quantitative 
images are not available, different levels of individualisation can be applied to the 
PBPK model for treatment planning (the more individualised, the better) [16].   
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Lastly, the short simulation time (< 3 min for 51 peptide amounts) allows feasible 
implementation of the developed treatment planning algorithm in clinical routine.  
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6 CONCLUSIONS 
The results of the conducted in silico clinical trial indicate that the developed 
treatment planning algorithm can derive plans which produce a higher tumour control 
than the typically delivered plan within tolerated BED constraints for the OARs and 
considering limitations of the radiopharmaceutical synthesis. The results show that 
the typical plan may be insufficient to produce adequate tumour control after a 4-
cycle treatment with 177Lu-DOTATATE. In contrast, it was shown that the optimal 
plans derived with the developed treatment planning algorithm may produce 
adequate tumour control in most patients after 4 cycles of 177Lu-DOTATATE. This 
demonstrates the importance of individualised treatment planning in molecular 
radiotherapy.  
The simulated results confirm that both the kidneys and the red marrow need to be 
included in the treatment planning process for PRRT with 177Lu-DOTATATE. In 
addition, higher molar activities than those routinely used for 177Lu-DOTATATE may 
be required to achieve better therapeutic outcomes. Furthermore, the short 
computational time required to complete the individual optimisation process allows 
the developed algorithm to be feasibly implemented in clinical routine.  
Therefore, based on the expected advantages of the developed treatment planning 
algorithm, this algorithm is proposed for clinical validation and potential future 
implementation in treatment planning in molecular radiotherapy. 
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7 SUMMARY 
Peptide-receptor radionuclide therapy (PRRT) is a modality of molecular radiotherapy 
in which patients are administered with radiolabelled peptides targeting peptide-
receptors overexpressed in some types of tumours. PRRT has shown promising 
results in the treatment of tumours with high expression of somatostatin receptors 
(e.g. neuroendocrine tumours (NETs) and meningioma). However, this therapeutic 
modality potentially produces high radiotoxicity in the kidneys and in the red bone 
marrow (RM), the kidneys usually being the dose-limiting organ in PRRT. To safely 
applied PRRT to patients producing an increased therapeutic effect, individualised 
treatment planning is required. Recently, it was shown that individually choosing an 
optimal combination of radiopharmaceutical amount and activity may lead to higher 
therapeutic indices (i.e. the ratio between the tumour dose and the dose in the dose-
limiting organ). However, some additional features are required during treatment 
planning to achieve a clinical applicability in PRRT: 
1. Multiple tumour lesions/metastases need to be considered simultaneously.  
2. Multiple potentially dose-limiting organs need to be included. 
3. Constraints in the radiopharmaceutical synthesis need to be accounted for. 
Therefore, the aim of this work was to develop a treatment planning algorithm for 
PRRT which can be applied clinically. Additionally, an in silico (i.e. based on 
computational simulations) clinical trial was conducted to demonstrate the 
applicability and advantages of the developed algorithm. 
To allow the developed algorithm to be applied for patients with multiple metastases 
the concept of overall biologically effective dose (oBED) was developed. oBED is a 
biologically effective dose (BED) value computed considering the total number of 
killed cells after radiotherapy and that can be used to represent organs/tissues with 
inhomogeneous characteristics or distribution (e.g. multiple tumour lesions). 
Therefore, maximising the tumour oBED during treatment planning will derive plans 
producing the maximum number of killed tumour cells among selected tumour 
lesions. In addition, the developed treatment planning algorithm incorporates multiple 
potentially dose-limiting organs and considers the maximum molar activity (i.e. the 
ratio between activity and amount) which can be achieved during the 
radiopharmaceutical synthesis. Thus, the developed treatment plan algorithm derives 
PRRT plans which maximise the total number of tumour cells within tolerated dose 
values for multiple organs at risk (OARs) and that considers the maximum achievable 
molar activity in the radiopharmaceutical synthesis. 
An in silico clinical trial was conducted with nine virtual patients created by fitting a 
physiologically-based pharmacokinetic (PBPK) model to 111In-DOTATATE 
pharmacokinetic data from nine patients with NETs or meningioma. The virtual 
patients were subsequently adapted to 177Lu-DOTATATE by changing the nuclide 
half-life in the virtual patients. In this trial, plans individually derived with the 
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developed algorithm were compared with the routinely delivered plan for 177Lu-
DOTATATE. Comparison between the optimal plans and the typical plan was drawn 
considering the tumour BED and the overall tumour control probability (oTCP). 
Complete plans (i.e. after 4 cycles of 177Lu-DOTATATE) leading to oTCP values 
higher than 99% were considered as plan producing adequate tumour control. 
The results of the conducted in silico clinical trial show that the plans derived with the 
developed algorithm produce considerably higher tumour BED values that the typical 
plan. In addition, the plans derived with the developed algorithm produced adequate 
tumour control in most (6 out of 9) virtual patients while the typical plan produced 
adequate tumour control in only 2 virtual patients. Therefore, based on the expected 
advantages, the developed algorithm is proposed for clinical validation and potential 
clinical implementation.  
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APPENDIX A: ABSORBED DOSE CALCULATIONS 
In this work, because of the short penetration depth of 177Lu (1.7 mm), only radiation 
produced in each respective organ/lesion (i.e.            for       in Eq. (6)) was 
considered for absorbed dose calculations in the tumour lesions, kidneys, liver and 
spleen. For the RM, as it is a distributed organ with high radiosensitivity, radiation 
produced in every organ included in the PBPK model was considered.   
Dose factors for 177Lu for the OARs where extracted from OLINDA/EXM [44] and 
scaled based on the size of the target organ. The scaling factor (   ) for the dose 
factors was defined as: 
    
           
           
                   (A1) 
where             is the mass of the target organ in the patient (measured or scaled) 
and             is the mass of the target organ used in OLINDA/EXM [44]. Dose 
factors for the RM where scaled based on patient body weight (Table II). Dose 
factors for 177Lu extracted from OLINDA/EXM for dose calculations are presented in 
Table A - I. 
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Table A - I. Dose factors for 
177
Lu from OLINDA/EXM [44]. 
Parameter Description Value  Unit 
SK←K 
dose factor from kidney to kidney 
(scaled using organ mass) 
4.82×10
-6
 Gy·min
-1
·MBq
-1
 
SL←L 
dose factor from liver to liver (scaled 
using organ mass) 
7.74×10
-7
 Gy·min
-1
·MBq
-1
 
SS←S 
dose factor from spleen to spleen 
(scaled using organ mass) 
7.86×10
-6
 Gy·min
-1
·MBq
-1
 
SRM←RM 
dose factor from red marrow to red 
marrow (scaled using body weight) 
7.14×10
-7
 Gy·min
-1
·MBq
-1
 
SRM←REM 
dose factor from remainder to red 
marrow (scaled using body weight) 
4.83×10
-9 a
 Gy·min
-1
·MBq
-1
 
SRM←AD 
dose factor from adrenal glands to red 
marrow (scaled using body weight) 
4.11×10
-9
 Gy·min
-1
·MBq
-1
 
SRM←L 
dose factor from liver to red marrow 
(scaled using body weight) 
1.39×10
-9
 Gy·min
-1
·MBq
-1
 
SRM←S 
dose factor from spleen to red marrow 
(scaled using body weight) 
1.40×10
-9
 Gy·min
-1
·MBq
-1
 
SRM←GI 
b
 
dose factor from gastrointestinal track 
to red marrow (scaled using body 
weight) 
2.92×10
-9
 Gy·min
-1
·MBq
-1
 
SRM←MUS 
dose factor from muscle to red marrow 
(scaled using body weight) 
1.52×10
-9
 Gy·min
-1
·MBq
-1
 
SRM←LU 
dose factor from lungs to red marrow 
(scaled using body weight) 
1.84×10
-9
 Gy·min
-1
·MBq
-1
 
SRM←K 
dose factor from kidneys to red marrow 
(scaled using body weight) 
2.84×10
-9
 Gy·min
-1
·MBq
-1
 
SRM←BR 
dose factor from brain to red marrow 
(scaled using body weight) 
1.65×10
-9
 Gy·min
-1
·MBq
-1
 
SRM←HRT 
dose factor from heart to red marrow 
(scaled using body weight) 
1.82×10
-9
 Gy·min
-1
·MBq
-1
 
SRM←RM 
c
 
dose factor from bone to red marrow 
(scaled using body weight) 
2.04×10
-7
 Gy·min
-1
·MBq
-1
 
SWB←WB 
dose factor from whole body to whole 
body (scaled using body weight) 
2.14×10
-8
 Gy·min
-1
·MBq
-1
 
a Value calculated based on Hindorf et al. [45] with data from OLINDA/EXM [44]. 
b Dose factor for the for the small intestine. 
c Dose factor for trabecular bone. 
 
Dose factors for 177Lu for the tumour lesions were fitted to published data [85] based 
on the tumour lesion mass. A tumour density of 1 g/ml was assumed. The data used 
for this fitting are presented in Table A - II. 
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Table A - II. Reported dose factors for 
177
Lu for tumour lesions based on tumour mass [85]. 
Tumour mass 
[g] 
Tumour dose factor 
[Gy∙min
-1
∙MBq
-1
] 
0.5 2.77×10
-3
 
1 1.40×10
-3
 
1.5 9.00×10
-4
 
2 7.02×10
-4
 
3 4.50×10
-4
 
4 3.52×10
-4
 
13 1.10×10
-4
 
17 8.30×10
-5
 
21 6.90×10
-5
 
29 4.80×10
-5
 
34 4.30×10
-5
 
52 2.67×10
-5
 
54 2.65×10
-5
 
 
The fitted function for the tumour dose factors used for the dose calculations is: 
            
      
                 
(   ⁄ )                
(   ⁄ )      (A2)  
where      is the dose factor for a tumour lesion [Gy∙min
-1∙MBq-1] and    is the 
mass of the tumour lesion [g]. The result of the fitting is presented in Figure A - I. 
 
 
Figure A - I. Fit of tumour dose factors for 
177
Lu-DOTATATE based on tumour mass. The 
adjusted R
2
 value of the fitting was 0.9998.  
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APPENDIX B: LIVER AND SPLEEN RESULTS 
Dose calculations for the liver and spleen for the optimal plans and for the typically 
delivered plan are presented in Table A - III. In this table, the molar activities for the 
optimal plans derived by using the developed treatment planning algorithm are also 
presented.  
 
Table A - III. Molar activities (MA) for the optimal plans and BEDs and absorbed doses (D) for the 
liver and spleen for the optimal plan and typically delivered plans. Results corresponding to 
simulations of the first cycle of 
177
Lu-DOTATATE PRRT for nine virtual patients. 
Virtual 
Patient 
(Tumour) 
 
Optimal Plan 
 
Typically delivered plan 
a
 
 
MA 
[MBq/nmol] 
BEDL [Gy2.5] 
(DL [Gy]) 
BEDS [Gy2.5] 
(DS [Gy]) 
 
BEDL [Gy2.5] 
(DL [Gy]) 
BEDS [Gy2.5] 
(DS [Gy]) 
VP1 (M) 
 
139 2.2 (2.2) 14.5 (12.5) 
 
0.75 (0.75) 4.3 (4.1) 
VP2 (M) 
 
125 1.8 (1.7) 15.0 (13.0) 
 
0.58 (0.58) 4.3 (4.1) 
VP3 (M) 
 
58 1.3 (1.3) 25.9 (21.0) 
 
0.47 (0.47) 9.3 (8.5) 
VP4 (M) 
 
205 1.2 (1.2) 16.0 (12.5) 
 
0.37 (0.37) 3.7 (3.4) 
VP5 (N) 
 
122 1.0 (1.0) 11.9 (9.67) 
 
0.64 (0.63) 6.1 (5.5) 
VP6 (N)
 b
 
 
257 1.6 (1.6) - 
 
0.52 (0.51) - 
VP7 (N) 
 
223 3.8 (3.6) 14.5 (12.1) 
 
0.81 (0.80) 2.7 (2.6) 
VP8 (N) 
 
143 2.1 (2.1) 18.1 (15.3) 
 
0.78 (0.78) 5.3 (5.0) 
VP9 (N) 
 
73 2.4 (2.3) 23.6 (17.7) 
 
1.4 (1.3) 11.8 (10.0) 
Median 
 
139 1.8 (1.7) 15.5 (12.8) 
 
0.64 (0.63) 4.8 (4.6) 
Min. 
 
58 1.0 (1.0) 11.9 (9.7) 
 
0.37 (0.37) 2.7 (2.6) 
Max. 
 
257 3.8 (3.6) 25.9 (21.0) 
 
1.4 (1.3) 11.8 (10.0) 
a
 Molar activity for the typically delivered plan = 28 MBq/nmol. 
b
 Splenectomy. 
MA, molar activity; M, meningioma; N, neuroendocrine tumour; D, absorbed dose. 
Subscripts L and S stand for liver and spleen, respectively. 
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